Volume 4 Supplement 2
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts
- Sonja Althammer1,
- Keith Steele2,
- Marlon Rebelatto2,
- Tze Heng Tan1,
- Tobias Wiestler1,
- Guenter Schmidt1,
- Brandon Higgs2Email author,
- Xia Li2,
- Li Shi2,
- Xiaoping Jin2,
- Joyce Antal2,
- Ashok Gupta2,
- Koustubh Ranade2,
- Gerd Binning1,
- Joaquim Bellmunt3,
- Ronald de Wit4,
- David J. Vaughn5,
- Yves Fradet6,
- Jae Lyun Lee7,
- Lawrence Fong8,
- Nicholas J. Vogelzang9,
- Miguel A. Climent10,
- Daniel P. Petrylak11,
- Toni K. Choueiri5,
- Andrea Necchi12,
- Winald Gerritsen13,
- Howard Gurney14,
- David I. Quinn15,
- Stéphane Culine16,
- Cora N. Sternberg17,
- Yabing Mai18,
- Markus Puhlmann18,
- Rodolfo F. Perini18,
- Dean F. Bajorin19,
- Padmanee Sharma20Email author,
- Margaret K. Callahan21,
- Emiliano Calvo22,
- Joseph W. Kim23,
- Filipo de Braud24,
- Patrick A. Ott25,
- Petri Bono26,
- Rathi N. Pillai27,
- Michael Morse28,
- Dung T. Le29,
- Matthew Taylor30,
- Pavlina Spilliopoulou31,
- Johanna Bendell32,
- Dirk Jaeger33,
- Emily Chan34,
- Scott J. Antonia35,
- Paolo A. Ascierto36,
- Delphine Hennicken37,
- Marina Tschaika37,
- Alex Azrilevich37,
- Jonathan Rosenberg21,
- Ofer Levy38,
- Christopher Chan39,
- Gady Cojocaru38,
- Spencer Liang39,
- Eran Ophir38,
- Sudipto Ganguly40,
- Amir Toporik38,
- Maya Kotturi39,
- Tal Fridman Kfir38,
- Benjamin M. Murter40,
- Kathryn Logronio39,
- Liat Dassa38,
- Ling Leung39,
- Shirley Greenwald38,
- Meir Azulay38,
- Sandeep Kumar39,
- Zoya Alteber38,
- Xiaoyu Pan41,
- Arthur Machlenkin38,
- Yair Benita38,
- Andrew W. Drake39,
- Ayelet Chajut38,
- Ran Salomon38,
- Ilan Vankin38,
- Einav Safyon38,
- John Hunter39Email author,
- Zurit Levine38,
- Mark White39,
- Rom Leidner42Email author,
- Hyunseok Kang43,
- Robert Haddad44,
- Neil H. Segal45,
- Lori J. Wirth46,
- Robert L. Ferris47,
- F. Stephen Hodi44,
- Rachel E. Sanborn48,
- Thomas F. Gajewski49,
- William Sharfman50,
- Dan McDonald51,
- Shivani Srivastava51,
- Xuemin Gu51,
- Penny Phillips51,
- Chaitali Passey51,
- Tanguy Seiwert49,
- Tsadik Habtetsion52Email author,
- Gang Zhou52,
- Donastas Sakellariou-Thompson53Email author,
- Cara Haymaker53,
- Caitlin Creasy53,
- Mark Hurd53,
- Naohiro Uraoka53,
- Jaime Rodriguez Canales53,
- Scott Koptez53,
- Patrick Hwu53,
- Anirban Maitra53,
- Chantale Bernatchez53,
- Scott M. Coyle54,
- Kole T. Roybel54,
- Levi J. Rupp54,
- Stephen P. Santoro54Email author,
- Stephanie Secrest54,
- Michael Spelman54,
- Hanson Ho54,
- Tina Gomes54,
- Tiffany Tse54,
- Chia Yung-Wu55,
- Jack Taunton56,
- Wendell Lim56,
- Peter Emtage54,
- Tarsem Moudgil57,
- Carmen Ballesteros-Merino57,
- Traci Hilton58,
- Christopher Paustian58,
- Rom Leidner59,
- David Page60,
- Walter Urba60,
- Bernard Fox57Email author,
- Bryan Bell59,
- Ashish Patel57,
- Tove Olafsen61,
- Daulet Satpayev62,
- Michael Torgov61,
- Filippo Marchioni61,
- Jason Romero61,
- Ziyue Karen Jiang61,
- Charles Zamilpa61,
- Jennifer S. Keppler61,
- Alessandro Mascioni61,
- Fang Jia61,
- Chen-Yu Lee61,
- Jean Gudas61Email author,
- Ryan J. Sullivan63Email author,
- Yujin Hoshida64,
- Theodore Logan65,
- Nikhil Khushalani66,
- Anita Giobbie-Hurder67,
- Kim Margolin68,
- Joanna Roder69,
- Rupal Bhatt70,
- Henry Koon71,
- Thomas Olencki72,
- Thomas Hutson73,
- Brendan Curti74,
- Shauna Blackmon75,
- James W. Mier70,
- Igor Puzanov76,
- Heinrich Roder69,
- John Stewart77,
- Asim Amin78,
- Marc S. Ernstoff76,
- Joseph I. Clark79,
- Michael B. Atkins80,
- Howard L. Kaufman81,
- Jeffrey Sosman82,
- Sabina Signoretti70,
- David F. McDermott70,
- Abraham A. Anderson83Email author,
- Igor Puzanov84,
- Mohammed M. Milhem85,
- Robert H. I. Andtbacka86,
- David Minor87,
- Kevin S. Gorski83,
- Daniel M. Baker83,
- Omid Hamid88,
- Howard L. Kaufman89,
- Emmanuel Akporiaye90Email author,
- Brendan Curti91,
- Yoshinobu Koguchi91,
- Rom Leidner92,
- Kim Sutcliffe92,
- Kristie Conder92,
- Walter Urba91,
- Thomas Marron93Email author,
- Nina Bhardwaj93,
- Linda Hammerich93,
- Fiby George93,
- Seunghee Kim-Schulze93,
- Tibor Keler94,
- Tom Davis94,
- Elizabeth Crowley94,
- Andres Salazar95,
- Joshua Brody96,
- Arta Monjazeb97Email author,
- Megan E. Daly98,
- Jonathan Riess98,
- Tianhong Li98,
- William J. Murphy97,
- Karen Kelly98,
- Zhiwei Hu99Email author,
- Rulong Shen100,
- Amanda Campbell100,
- Elizabeth McMichael100,
- Lianbo Yu100,
- Bhuvaneswari Ramaswam100,
- Cheryl A. London100,
- Tian Xu101,
- William Carson100,
- Kathleen M. Kokolus102Email author,
- Elizabeth A. Repasky103,
- Todd D. Schell102,
- Joseph D. Drabick102,
- David J. Messenheimer104Email author,
- Shawn Jensen105,
- Bernard Fox105,
- Mark Rubinstein106Email author,
- Kristina Andrijauskaite106,
- Marzena Swiderska-syn106,
- Kristin Lind107,
- Agnes Choppin107,
- Marina K. Roell107,
- John Wrangle108,
- Kristina Andrijauskaite108,
- Marzena Swiderska-syn108,
- Peter Rhode109,
- Hing Wong109,
- Mark Rubinstein108Email author,
- Shamim Ahmad110,
- Mason Webb110,
- Rasha Abu-Eid110,
- Rajeev Shrimali110,
- Vivek Verma110,
- Atbin Doroodchi110,
- Zuzana Berrong110,
- David Yashar110,
- Raed Samara111,
- Mikayel Mkrtichyan110,
- Samir Khleif110Email author,
- Steven Powell112Email author,
- Mark Gitau113,
- Christopher Sumey112,
- Andrew Terrell2,
- Michele Lohr112,
- Ryan K. Nowak112,
- Steven McGraw114,
- Ash Jensen113,
- Miran Blanchard113,
- Kathryn A. Gold115,
- Ezra E. W. Cohen115,
- Christie Ellison112,
- Lora Black112,
- John Lee116,
- William Chad Spanos112,
- Erik Wennerberg117Email author,
- Emily Schwitzer118,
- Claire Lhuillier117,
- Graeme Koelwyn119,
- Rebecca Hiner118,
- Lee Jones118,
- Sandra Demaria120,
- Vandeveer Amanda121Email author,
- John W. Greiner121,
- Jeffrey Schlom121,
- Michelle Bookstaver122Email author,
- Christopher M. Jewell,
- Christopher Paustian123Email author,
- Andrew Gunderson124,
- Brian Boulmay124,
- Rui Li125,
- Bradley Spieler126,
- Kyle Happel126,
- Tarsem Moudgil127,
- Zipei Feng128,
- Carmen Ballesteros-Merino125,
- Christopher Dubay128,
- Brenda Fisher129,
- Yoshinobu Koguchi130,
- Sandra Aung123,
- Eileen Mederos126,
- Carlo B. Bifulco125,
- Michael McNamara131,
- Keith Bahjat131,
- William Redmond131,
- Augusto Ochoa126,
- Hong-Ming Hu132,
- Adi Mehta133,
- Fridtjof Lund-Johansen133,
- Bernard Fox128,
- Walter Urba130,
- Rachel E. Sanborn130,
- Traci Hilton123,
- Frank Bedu-Addo134,
- Greg Conn134,
- Michael King134,
- Panna Dutta134,
- Robert Shepard135Email author,
- Mark Einstein136,
- Sylvia Adams137Email author,
- Ena Wang138,
- Ping Jin139,
- Yelena Novik137,
- Debra Morrison137,
- Ruth Oratz137,
- Franco M. Marincola138,
- David Stroncek140,
- Judith Goldberg137,
- Sandra Demaria141,
- Silvia C. Formenti141,
- Jérôme Galon142,
- Bernhard Mlecnik142,
- Florence Marliot142,
- Fang-Shu Ou143,
- Carlo B. Bifulco144,
- Alessandro Lugli145,
- Inti Zlobec145,
- Tilman T. Rau145,
- Iris D. Nagtegaal146,
- Elisa Vink-Borger146,
- Arndt Hartmann147,
- Carol Geppert147,
- Michael H. Roehrl148,
- Prashant Bavi148,
- Pamela S. Ohashi148,
- Julia Y. Wang148,
- Linh T. Nguyen148,
- SeongJun Han148,
- Heather L. MacGregor148,
- Sara Hafezi-Bakhtiari148,
- Bradley G. Wouters148,
- Yutaka Kawakami149,
- Boryana Papivanova149,
- Mingli Xu149,
- Tomonobu Fujita149,
- Shoichi Hazama150,
- Nobuaki Suzuki150,
- Hiroaki Nagano150,
- Kiyotaka Okuno151,
- Kyogo Itoh152,
- Eva Zavadova153,
- Michal Vocka153,
- Jan Spacek153,
- Lubos Petruzelka153,
- Bohuslav Konopasek153,
- Pavel Dundr153,
- Helena Skalova153,
- Toshihiko Torigoe154,
- Noriyuki Sato154,
- Tomohisa Furuhata154,
- Ichiro Takemasa154,
- Marc Van den Eynde155,
- Anne Jouret-Mourin155,
- Jean-Pascal Machiels155,
- Tessa Fredriksen142,
- Lucie Lafontaine142,
- Bénédicte Buttard142,
- Sarah Church142,
- Pauline Maby142,
- Helen Angell142,
- Mihaela Angelova142,
- Angela Vasaturo142,
- Gabriela Bindea142,
- Anne Berger142,
- Christine Lagorce142,
- Prabhu S. Patel156,
- Hemangini H. Vora156,
- Birva Shah156,
- Jayendrakumar B. Patel156,
- Kruti N. Rajvik156,
- Shashank J. Pandya156,
- Shilin N. Shukla156,
- Yili Wang157,
- Guanjun Zhang157,
- Giuseppe V. Masucci158,
- Emilia K. Andersson158,
- Fabio Grizzi159,
- Luigi Laghi159,
- Gerardo Botti160,
- Fabiana Tatangelo160,
- Paolo Delrio160,
- Gennaro Cilberto160,
- Paolo A. Ascierto160,
- Franco Marincola161,
- Daniel J. Sargent143,
- Bernard A. Fox144Email author,
- Alain Algazi162,
- Katy Tsai162,
- Michael Rosenblum162,
- Prachi Nandoskar162,
- Robert H. I. Andtbacka163,
- Amy Li162,
- John Nonomura164,
- Kathryn Takamura164,
- Mary Dwyer164,
- Erica Browning164,
- Reneta Talia164,
- Chris Twitty164,
- Sharron Gargosky164Email author,
- Jean Campbell164,
- Carmen Ballesteros-Merino165,
- Carlo B. Bifulco4,
- Bernard Fox165,
- Mai Le166,
- Robert H. Pierce164,
- Adil Daud162,
- Robyn Gartrell167Email author,
- Douglas Marks167,
- Edward Stack168,
- Yan Lu167,
- Daisuke Izaki169,
- Kristen Beck170,
- Dan Tong Jia170,
- Paul Armenta170,
- Ashley White-Stern170,
- Yichun Fu170,
- Zoe Blake167,
- Howard L. Kaufman171,
- Bret Taback1,
- Basil Horst167,
- Yvonne M. Saenger172,
- Steven Leonardo173Email author,
- Keith Gorden173,
- Ross B. Fulton173,
- Kathryn Fraser173,
- Takashi O. Kangas173,
- Richard Walsh173,
- Kathleen Ertelt173,
- Jeremy Graff173,
- Mark Uhlik173,
- Jennifer S. Sims174Email author,
- Liang Lei174,
- Takashi Tsujiuchi174,
- Jeffrey N. Bruce174,
- Peter Canoll174,
- Anthony W Tolcher175,
- Evan W Alley176,
- Gurunadh Chichili177,
- Jan E Canoll178,
- Paul Moore177,
- Ezio Bonvini177,
- Syd Johnson177,
- Sadhna Shankar177,
- James Vasselli177,
- Jon Wigginton177 and
- John Powderly179
© The Author(s). 2016
Published: 8 December 2016
Biomarkers and Immune Monitoring
O1 Combinatorial CD8+ and PD-L1+ cell densities correlate with response and improved survival in non-small cell lung cancer (NSCLC) patients treated with durvalumab
Sonja Althammer1, Keith Steele2, Marlon Rebelatto2, Tze Heng Tan1, Tobias Wiestler1, Guenter Schmidt1, Brandon Higgs2, Xia Li2, Li Shi2, Xiaoping Jin2, Joyce Antal2, Ashok Gupta2, Koustubh Ranade2, Gerd Binning1
1Definiens AG, Munich, Bayern, Germany; 2MedImmune, Gaithersburg, MD, USA
Correspondence: Brandon Higgs (email@example.com)
Immunotherapies have improved patient responses and survival, though not all patients benefit. Effective biomarkers may help to improve outcomes. Durvalumab is a human IgG1 monoclonal antibody that inhibits PD-L1 binding to PD-1 and CD80, restoring antitumor immunity [1, 2]. PD-L1 expression on tumor or tumor-infiltrating immune cells measured manually with different immunohistochemistry (IHC) assays can enrich for patients responding to anti-PD-1/PD-L1 agents. Tumor-infiltrating cytotoxic CD8+ T cells may also have potential predictive utility for therapeutic response. We explored automated image analysis and pattern recognition of tumor biopsies to determine whether CD8+ and PD-L1+ cell densities could better identify patients most likely to respond to durvalumab than PD-L1 IHC alone.
CP1108/NCT01693562 was a nonrandomized phase I/II trial evaluating durvalumab in advanced NSCLC and other solid tumors . By 29APR2016, 304 previously treated NSCLC patients, median 3 prior lines, received 10 mg/kg of durvalumab q2w ≤12 months. Baseline archived or fresh tumor biopsies were analyzed for PD-L1 (Ventana/SP263) and CD8 (Ventana/SP239) by IHC. For the marker combination, slides were scored using the product of PD-L1+ and CD8+ cell densities with Definiens’ Developer XD 2.1.4 software. For PD-L1 alone, ≥25% tumor cells stained for PD-L1 at any intensity were scored positive. Clinical outcomes (ORR, PFS and OS) were analysed based on CD8+ and PD-L1+ densities (n = 163 available) and PD-L1 alone in pre-treatment biopsies using a discovery (n = 84) and validation (n = 79) set. Datasets were matched on baseline PD-L1 status, histology, ECOG, lines of therapy, and response.
Patients with high pretreatment CD8+ and PD-L1+ densities (prevalence = 36%) had better ORR, OS, and PFS compared to those with low CD8+ and PD-L1+ densities (Fig. 1), as well as high PD-L1 expression alone.
Automated image analysis of CD8+ and PD-L1+ cell densities in baseline tumor biopsies may identify patients with improved outcomes to durvalumab.
ClinicalTrials.gov identifier NCT01693562.
1. MedImmune/AstraZeneca. Data on file.
2. Ibrahim R, Stewart R, Shalabi A: PD-L1 blockade for cancer treatment: MEDI4736. Semin Oncol 2015, 42:474–483.
Clinical Trials: Cutting-Edge (Completed Trials)
O2 Keynote-045: open-label, phase III study of pembrolizumab versus investigator’s choice of paclitaxel, docetaxel, or vinflunine for previously treated advanced urothelial cancer
Joaquim Bellmunt,1 Ronald de Wit,2 David J Vaughn,3 Yves Fradet,4 Jae Lyun Lee,5 Lawrence Fong,6 Nicholas J Vogelzang,7 Miguel A Climent,8 Daniel P Petrylak,9 Toni K Choueiri,1 Andrea Necchi,10 Winald Gerritsen,11 Howard Gurney,12 David I Quinn,13 Stéphane Culine,14 Cora N Sternberg,15 Yabing Mai,16 Markus Puhlmann,16 Rodolfo F Perini,16 Dean F Bajorin17
1Dana-Farber Cancer Institute, Boston, MA, USA; 2Erasmus MC Cancer Institute, Rotterdam, Netherlands; 3Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA; 4CHU de Québec-Université Laval, Québec, QC, Canada; 5Asan Medical Center and University of Ulsan College of Medicine, Seoul, South Korea; 6University of California, San Francisco, San Francisco, CA, USA; 7Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA; 8Fundación Instituto Valenciano de Oncología, Valencia, Spain; 9Smilow Cancer Hospital at Yale University, New Haven, CT, USA; 10Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; 11Radboud University Medical Center, Nijmegen, Netherlands; 12Westmead Hospital and Macquarie University, Sydney, NSW, Australia; 13Univeristy of Southern California Norris Comprehensive Cancer Center and Hospital, Los Angeles, CA, USA; 14Hôpital Saint-Louis, Paris, France; 15San Camillo Forlanini Hospital, Rome, Italy; 16Merck & Co., Inc., Kenilworth, NJ, USA; 17Memorial Sloan Kettering Cancer Center, New York, NY, USA
There is no standard second-line therapy for advanced urothelial cancer. Although paclitaxel, docetaxel, and vinflunine are commonly used, they provide limited clinical benefit. KEYNOTE-045 compared the efficacy and safety of the anti–PD-1 antibody pembrolizumab versus investigator-choice chemotherapy as second-line therapy for advanced urothelial cancer that progressed or recurred following first-line platinum-based chemotherapy.
Eligible patients were enrolled regardless of PD-L1 expression and randomized 1:1 to pembrolizumab 200 mg Q3W for 24 months or investigator’s choice of paclitaxel 175 mg/m2 Q3W, docetaxel 75 mg/m2 Q3W, or vinflunine 320 mg/m2 Q3W. Randomization was stratified by ECOG PS (0/1 vs 2), liver metastases (yes vs no), hemoglobin level (<10 vs ≥10 g/dL), and time from last chemotherapy dose (<3 vs ≥3 months). The study had a group sequential design to control for type I error. Primary endpoints were OS and PFS (RECIST v1.1 by blinded, independent central review). ORR was a key secondary endpoint. Differences in OS and PFS were assessed in the intention-to-treat population using the stratified log-rank test
Between November 5, 2014 and November 13, 2015, 542 patients from 29 countries were enrolled: 270 in the pembrolizumab arm, 272 in the chemotherapy arm. As of September 7, 2016, median follow-up was 9.0 months; 49 (18.4%) patients remained on pembrolizumab and 3 (1.2%) patients remained on chemotherapy. Baseline characteristics were generally balanced between arms, with 87.3% with visceral disease, 34.3% with liver metastases, 1.1% with ECOG PS 2, 81.5% with hemoglobin ≥10 g/dL, and 38.2% with <3 months since most recent chemotherapy. Pembrolizumab significantly improved OS over chemotherapy (HR 0.73, P = 0.0022; median 10.3 vs 7.4 months) (Table 1). There was no difference in PFS (HR 0.98, P = 0.42) (Table 1). ORR was significantly improved with pembrolizumab (21.1% vs 11.4%) (Table 1). Pembrolizumab was associated with fewer any-grade (60.9% vs 90.2%) grade 3-5 treatment-related AEs (15.0% vs 49.4%). 4 patients in each arm died due to treatment-related AEs.
Pembrolizumab demonstrated a statistically significant OS benefit over chemotherapy in the second-line advanced urothelial cancer setting, making it the first therapy to demonstrate a survival benefit over an active comparator in this population. The superior OS combined with the lower rate of any-grade and high-grade treatment-related AEs support pembrolizumab as a new standard of care for advanced urothelial cancer that progressed on/after platinum-based chemotherapy.
Efficacy in KEYNOTE-045
N = 270
N = 272
OS, no. of events
Median (95 % CI), months
HR (95 % CI)
0.73 (0.59-0.91); P = 0.0022
PFS, no. of events
Median (95 % CI), months
HR (95 % CI)
0.98 (0.81-1.19); P = 0.42
ORR (95 % CI)
21.1 % (16.4-26.5)
11.4 % (7.9-15.8)
Treatment difference, % (95 % CI)
9.6 (3.5-15.9); P = 0.0011
O3 Efficacy and safety of nivolumab plus ipilimumab in metastatic urothelial carcinoma: first results from the phase I/II CheckMate 032 study
Padmanee Sharma1, Margaret K Callahan2, Emiliano Calvo3, Joseph W Kim4, Filipo de Braud5, Patrick A Ott6, Petri Bono7, Rathi N Pillai8, Michael Morse9, Dung T Le10, Matthew Taylor11, Pavlina Spilliopoulou12, Johanna Bendell13, Dirk Jaeger14, Emily Chan15, Scott J Antonia16, Paolo A Ascierto17, Delphine Hennicken18, Marina Tschaika18, Alex Azrilevich18, Jonathan Rosenberg2
1University of Texas MD Anderson Cancer Center, Houston, TX, USA; 2Memorial Sloan Kettering Cancer Center, New York, NY, USA; 3START Madrid, Centro Integral Oncológico Clara Campal, Madrid, Spain; 4Yale Cancer Center, New Haven, CT, USA; 5Istituto Nazionale dei Tumori-Università degli Studi di Milano, Milano, Lombardia, Italy; 6Dana-Farber Cancer Institute, Boston, MA, USA; 7Comprehensive Cancer Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; 8Emory Winship Cancer Institute, Atlanta, GA, USA; 9Duke University Medical Center, Durham, NC, USA; 10Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, USA; 11Oregon Health & Science University, Portland, OR, USA; 12Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; 13Sarah Cannon Research Institute and Department of Medical Oncology, Tennessee Oncology, Nashville, TN, USA; 14Heidelberg University Hospital, Heidelberg, Baden-Wurttemberg, Germany; 15Vanderbilt-Ingram University Medical Center, Nashville, TN, USA; 16H. Lee Moffitt Cancer Center, Tampa, FL, USA; 17Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy, Napoli, Italy; 18Bristol-Myers Squibb, Princeton, NJ, USA
Correspondence: Padmanee Sharma (firstname.lastname@example.org)
Nivolumab is a programmed death-1 (PD-1) immune checkpoint inhibitor associated with clinical benefit in previously treated patients with metastatic urothelial carcinoma . Preclinical and clinical data indicate that the combination of nivolumab plus ipilimumab, an anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) antibody, can improve antitumor activity in other tumor types. Here, we report the first efficacy and safety results of combined nivolumab plus ipilimumab given at two different dosing schedules in CheckMate 032 , an open-label, multicenter, phase I/II study of patients with metastatic urothelial carcinoma who progressed after prior platinum-based therapy.
Patients with locally advanced or metastatic urothelial carcinoma previously treated with platinum-based therapy were included in the study. Patients were treated with either of two combination schedules, nivolumab 1 mg/kg + ipilimumab 3 mg/kg (N1I3) or nivolumab 3 mg/kg + ipilimumab 1 mg/kg (N3I1) every 3 weeks for four cycles, followed by nivolumab 3 mg/kg every 2 weeks; or they were treated with nivolumab monotherapy 3 mg/kg (N3) every 2 weeks. All patients were treated until disease progression or unacceptable toxicity. The primary endpoint was investigator-assessed objective response rate (ORR) by RECIST v1.1. Secondary endpoints included safety and duration of response (DoR).
Minimum follow-up was 3.9 months in the N1I3 (n = 26) group, 14.5 months in the N3I1 group (n = 104), and 13.8 months in N3 group (n = 78). ORR was 38.5% (95% confidence interval [CI], 20.2-59.4), 26.0% (95% CI, 17.9-35.5), and 25.6% (95% CI, 16.4-36.8) in the N1I3, N3I1, and N3 groups, respectively. Median DoR has not been reached in any treatment group. The frequency of drug-related grade 3-4 adverse events was 30.8% (N1I3), 31.7% (N3I1), and 23.1% (N3). Treatment-related adverse events led to discontinuation in 7.7% (N1I3), 13.5% (N3I1), and 3.8% (N3) of patients. One death was reported in the N3I1 group (pneumonitis) and two deaths were reported in the N3 group (pneumonitis and thrombocytopenia).
Second-line treatment with N1I3 may provide the most favorable benefit-risk ratio among the regimens studied. If these interim results are confirmed with longer follow-up, further development of the N1I3 combination in metastatic urothelial carcinoma is warranted.
ClinicalTrials.gov identifier NCT01928394.
1. Sharma P, Bono P, Kim JW, et al: Efficacy and safety of nivolumab monotherapy in metastatic urothelial cancer (mUC): Results from the phase I/II CheckMate 032 study. J Clin Oncol 2016, 34(15 suppl): Abstract 4501.
Coinhibition & Costimulation
O4 Computational identification, functional characterization, and antibody blockade of a new immune checkpoint in the TIGIT family of interacting molecules
Ofer Levy1, Christopher Chan2, Gady Cojocaru1, Spencer Liang2, Eran Ophir1, Sudipto Ganguly3, Amir Toporik1, Maya Kotturi2, Tal Fridman Kfir1, Benjamin M. Murter3, Kathryn Logronio2, Liat Dassa1, Ling Leung2, Shirley Greenwald1, Meir Azulay1, Sandeep Kumar2, Zoya Alteber1, Xiaoyu Pan4, Arthur Machlenkin1, Yair Benita1, Andrew W. Drake2, Ayelet Chajut1, Ran Salomon1, Ilan Vankin1, Einav Safyon1, John Hunter2, Zurit Levine1, Mark White2
1Compugen Ltd., Holon, Israel; 2Compugen Inc, USA, South San Francisco, CA, USA; 3Johns Hopkins University, Baltimore, MD, USA; 4Bloomberg ~ Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, Baltimore, MD, USA
Correspndence: John Hunter (email@example.com)
While antibody blockade of the CTLA-4 and PD-1 pathways has emerged as an effective treatment modality for cancer, the majority of patients do not derive long-term benefit, suggesting a need for targeting of additional immune checkpoints. Employing our unique computational algorithms to define new members of the B7/CD28 family, we identified PVRIG, which is expressed by multiple subsets of T and NK cells. We report here its expression pattern, functional characterization, and anti-tumor activity of blocking antibodies targeting this molecule.
Utilizing Compugen’s Predictive Discovery platform we identified PVRIG as a potential novel immune checkpoint, after which a retroviral cell screening library was used to identify its cognate binding counterpart. Target effects on T cell modulation were assessed with primary and tumor-derived T cell assays, taking advantage of target overexpression, knockdown, and antagonist antibody approaches. Antibodies against the human protein were screened for their ability to enhance T cell activation in vitro, while antibodies targeting the mouse orthologue were assessed in vivo for effects on tumor growth inhibition in syngeneic models.
A PVRIG-Fc-fusion protein was found to bind PVRL2, with binding specificity confirmed both by ELISA and flow cytometry analysis. PVRIG demonstrated unique expression kinetics upon T cell activation, with detection of the target on memory T cells, as well as on NK cells and γδ T cells. A panel of high affinity human antibodies with the ability to block interaction of PVRIG with PVRL2 were generated, which when tested in vitro were shown to enhance activation of both primary CD4+ and tumor-derived CD8+ T cells through a PVRL2-dependent mechanism. The lead antibody, COM-701, is currently in preclinical development. Since COM-701 is not mouse cross-reactive, in vivo studies were conducted with a surrogate blocking anti-mouse PVRIG antibody. When combined with anti-PD-L1 blockade, anti-mouse PVRIG inhibits growth of established tumors in both the CT26 and MC38 colorectal cancer models. Combination testing with additional immune checkpoint inhibitors, as well as in PVRIG knockout mice, is ongoing.
We describe the identification of PVRIG as a novel immune checkpoint on T cells, as well the development of a high affinity antagonistic antibody, COM-701, that is currently in preclinical development. COM-701 is able to enhance human T cell activation, and a surrogate antibody with similar characteristics shows synergy with PD-L1 in vivo in multiple syngeneic models. Overall, our data demonstrate the utility of targeting PVRIG in addition to other B7 family checkpoints for the treatment of cancer.
O5 Preliminary efficacy from a phase I/II study of the natural killer cell–targeted antibody lirilumab in combination with nivolumab in squamous cell carcinoma of the head and neck
Rom Leidner1, Hyunseok Kang2, Robert Haddad3, Neil H Segal4, Lori J Wirth5, Robert L Ferris6, F Stephen Hodi3, Rachel E Sanborn7, Thomas F Gajewski8, William Sharfman9, Dan McDonald10, Shivani Srivastava10, Xuemin Gu10, Penny Phillips10, Chaitali Passey10, Tanguy Seiwert8
1Earle A. Chiles Research Institute, Robert W. Franz Cancer Center, Providence Portland Medical Center, Portland, OR, USA; 2Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA; 3Dana-Farber Cancer Institute, Boston, MA, USA; 4Memorial Sloan Kettering Cancer Center, New York, NY, USA; 5Massachusetts General Hospital, Boston, MA, USA; 6University of Pittsburg, Pittsburgh, PA, USA; 7Earle A. Chiles Research Institute, Providence Cancer Center, Portland, OR, USA; 8University of Chicago Medical Center, Chicago, IL, USA; 9The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Lutherville, MD, USA; 10Bristol-Myers Squibb, Princeton, NJ, USA
Correspondence: Rom Leidner (firstname.lastname@example.org)
Natural killer (NK) cells and the innate immune system play a critical role in immunosurveillance, control of tumor growth, and metastasis. NK-cell activation is negatively regulated by inhibitory killer-cell immunoglobulin-like receptors (KIRs); therefore, blocking KIR function may potentiate an anti-tumor immune response and complement other immuno-oncology therapies that enhance T cell activity. We present preliminary efficacy results in patients with squamous cell carcinoma of the head and neck (SCCHN) from a phase I/II study of lirilumab, a fully human monoclonal antibody that blocks inhibitory KIRs on NK cells, in combination with nivolumab, a fully human IgG4 monoclonal antibody that targets the PD-1 receptor, in patients with solid tumors (NCT01714739).
During dose escalation, patients with advanced solid tumors who progressed after ≥ 1 prior therapy received lirilumab 0.1–3.0 mg/kg once every 4 weeks (Q4W) plus nivolumab 3.0 mg/kg Q2W. Cohort expansion was initiated at the maximum dose of lirilumab 3.0 mg/kg Q4W plus nivolumab 3.0 mg/kg Q2W in patients with advanced solid tumors. Key study endpoints include safety (primary), objective response rate (ORR), disease control rate (DCR), duration of response (DOR), and biomarker assessments.
As of the August 30, 2016 data cutoff, 159 patients were treated with the lirilumab plus nivolumab combination. Treatment-related adverse events (TRAEs) and grade 3–4 TRAEs were reported in 72% (114/159) and 15% (24/159) of patients, respectively. Discontinuations due to TRAEs occurred in 8% (12/159). Of the 41 patients with SCCHN treated, 29 were evaluable for response. In this heavily pretreated, checkpoint inhibitor–naïve group, ORR was 24% (7/29; confirmed and unconfirmed) and DCR was 52% (15/29). Maximum reduction in target lesions are presented in Fig. 2 for 26 patients with available tumor assessments. Two patients classified as stable disease per RECIST v1.1 showed unconventional responses, with 100% and 37% reductions in target lesions. Among evaluable patients, five (17%) had reductions in tumor burden > 80%. Responses appear durable, with the median DOR not reached (Fig. 3). Updated efficacy and preliminary biomarker analyses (including PD-L1 and HPV status) will be presented.
Preliminary efficacy of lirilumab plus nivolumab in patients with advanced platinum-refractory SCCHN demonstrates clinical benefit, with encouraging response rates that were deep and durable responses in some patients. This combination demonstrated a manageable safety profile similar to that observed with nivolumab monotherapy. Further evaluation of this novel combination of an NK-cell inhibitor and an immune checkpoint inhibitor is ongoing.
06 Phase II study of intratumoral plasmid interleukin 12 (pIL-12) with electroporation in combination with pembrolizumab in stage III/IV melanoma patients with low tumor infiltrating lymphocytes
Alain Algazi1, Katy Tsai1, Michael Rosenblum1, Prachi Nandoskar1, Robert HI Andtbacka2, Amy Li1, John Nonomura3, Kathryn Takamura3, Mary Dwyer3, Erica Browning3, Reneta Talia3, Chris Twitty3, Sharron Gargosky3, Jean Campbell3, Carmen Ballesteros-Merino4, Carlo B. Bifulco4, Bernard Fox4, Mai Le5, Robert H Pierce3, Adil Daud1
1University of California, San Francisco, San Francisco, CA, USA; 2Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA; 3OncoSec Medical Inc., San Diego, CA, USA; 4Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Cancer Center, Portland, Oregon, USA; 5Doctor Hope, LLC, San Diego, CA, USA
Correspondence: Sharron Gargosky (email@example.com)
Low tumor infiltrating lymphocytes (TIL) are predictive for poor response to immunotherapy with anti-PD-1/PD-L1 agents. We have shown that melanoma patients with a low frequency of PD-1hiCTLA-4 + TIL are unlikely to respond to pembrolizumab (Daud2016). Intratumoral electroporation of pIL-12 (IT-pIL12-EP) leads to an IFN-g signature suggestive of increased TIL as well as regression in both treated and untreated lesions. We hypothesize that combination IT-pIL12-EP and pembrolizumab will improve clinical outcomes in this low-response population. Preliminary results from a multi-center, phase II, open-label trial testing this hypothesis are presented.
Melanoma stage III/IV patients with accessible lesions were consented and enrolled if they had a TIL status of hiCTLA-4+ in the CD45 + CD8 + CD3+ gate by flow cytometry (FC). Patients were treated with pembrolizumab (200 mg every 3 weeks) concurrently with IT-pIL12-EP on days 1, 5 and 8 every 6 weeks. Patients were evaluated for overall response rate (ORR) every 12 weeks by RECISTv1.1. Pre and post-treatment blood and tumor specimens were collected, and analyzed for immune phenotyping, gene expression, TCR diversity, and changes in the tumor microenvironment with multispectral immunohistochemistry.
Interim ORR data is available on 15 patients. 13/15 patients had a frequency of PD-1hi CTLA-4+ TIL of < 22% (low TIL status), phenotypes associated with a low probability of response to anti-PD-1 (Daud 2016). These 15 patients age 39-89 years, were 53% male, 66% stage III and 34% stage IV. Treatment was well tolerated; 38% of adverse events (AE) were classified as treatment site reactions (grade 1-2) that resolved. One SAE of cellulitis resolved with 5d antibiotics. One grade 3 AE of diarrhea resolved with corticosteroids. The ORR was 40% (4CR, 2PR) by RECISTv1.1. Analysis of tumor biopsies and blood demonstrated meaningful immunological changes including an increased number and ratio of CD8+:PD-L1+ and CD8+:FoxP3 + TIL, tumoral RNA signatures indicating an increase in CD8 and IFN-γ-related gene expression and concordant immune phenotypes in the periphery.
The combination IT-pIL12-EP with pembrolizumab in patients with an anti-PD-1 non-responsive phenotype engendered a 40% clinical response with associated positive immune-based biomarker data and an excellent safety profile. These data suggests that IT-pIL12-EP modulates the tumor microenvironment to enable an effective anti-PD-1 mAb response in patients otherwise unlikely to respond.
We thank Merck and Oncosec for supporting this trial with pembrolizumab and IT-pIL-12, respectfully.
ClinicalTrials.gov identifier: NCT02493361
1. Daud AI, Loo K, Pauli ML, Sanchez-Rodriguez R, Sandoval PM, Taravati K, et al: Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma. J Clin Invest 2016, 126(9):3447–3452.
Adoptive Cellular Therapy
P1 Chemo-immunotherapy with cyclophosphamide and tumor reactive CD4+ T cells lead to destruction of tumor vasculature and eventual tumor eradication
Tsadik Habtetsion, Gang Zhou
Augusta University, Augusta, GA, USA
Correspondence: Tsadik Habtetsion (firstname.lastname@example.org)
CD4+ T cells are critical components of anti-tumor immunity and play a pivotal role in orchestrating anti-tumor immune responses. Mounting evidence from preclinical and clinical studies indicates that CD4+ T cells in combination with chemotherapy can control tumor growth and recurrence. CD4+ T cells are suggested to mediate tumor rejection through mechanisms that include cytotoxic effects on tumor cells, inhibition of angiogenesis, and reprogramming of the tumor microenvironment.
In this project, we set out to study the cellular and molecular mechanisms underlying the therapeutic effect of chemo-immunotherapy in the form of cyclophosphamide (CTX) and tumor specific CD4+ T cells in a murine model of colorectal cancer. Mice were injected subcutaneously with colorectal cancer cells. When the tumor reached 140-160 mm2 in area, mice were injected with a low dose of cyclophosphamide followed by adoptive transfer of tumor reactive CD4+ T cells.
In a murine model of colorectal cancer, we show that the combination therapy of CTX and tumor reactive CD4+ T cells resulted in enhanced necrosis of tumor cells in vivo, leading to eventual eradication of advanced tumors. By using immunofluorescence staining and blood perfusion imaging, we demonstrated that the combination therapy leads to destruction of the established tumor vasculature and reduced blood supply to tumor tissue. Furthermore, we assessed blood vessel permeability in the tumor tissue and found that the combination therapy increased extravasation of Evans blue dye, suggesting an increase in vascular permeability.
In summary, our findings suggest that the combination therapy of CTX + CD4+ T cells leads to destruction of the tumor vasculature, resulting in extensive necrosis of tumor tissue and eventual tumor regression. These findings may provide new insights into mechanisms of tumor rejection by CD4+ T cells.
P2 Preclinical development of tumor-infiltrating lymphocyte therapy for pancreatic cancer
Donastas Sakellariou-Thompson, Cara Haymaker, Caitlin Creasy, Mark Hurd, Naohiro Uraoka, Jaime Rodriguez Canales, Scott Koptez, Patrick Hwu, Anirban Maitra, Chantale Bernatchez
University of Texas MD Anderson Cancer Center, Houston, TX, USA
Correspondence: Donastas Sakellariou-Thompson (email@example.com)
Immunotherapy has become an effective cancer therapy, particularly in the case of checkpoint blockade and adoptive T cell therapy (ACT). ACT exploits the presence of tumor-infiltrating lymphocytes (TIL) by exponentially expanding their numbers ex vivo and re-infusing them into the patient in an autologous setting. With the effectiveness of TIL therapy already well established in multiple phase II studies in melanoma, there is a push to translate it to other cancers in dire need of improved therapies. Pancreatic ductal adenocarcinoma (PDAC) is one such cancer for which the current therapy, surgery and chemotherapy, provides an overall 5-year survival rate of only 5%. The presence of TIL is correlated with increased survival in PDAC, which suggests that TIL could effectively control the disease and provides a rationale to test TIL therapy in this setting.
To assess the feasibility, we characterized the immune component of PDAC, explored the ability to grow and expand TIL from tumor fragments, and analyzed the clonality of these expanded TIL.
Flow cytometry analysis detected low, CD4-rich T cell infiltration. These TIL were able to be expanded ex vivo and the addition of an agonistic anti-41BB antibody to the cultures preferentially increased total TIL outgrowth, particularly that of CD8+ TIL. The success rate of TIL growth was increased from 23% to 50% for cultures grown without and with anti-41BB respectively. Sequencing of the T cell receptor CDR3-beta chain found specific T cell clones enriched at the tumor site in comparison to the blood. IHC staining for MHC class I (MHCI) on PDAC tumor samples showed that it is widely expressed but at low levels generally.
In conclusion, it is possible to expand CD8+ T cells from PDAC bearing TCR sequences highly enriched in the tumor. Additionally, expanded TIL would be able to target tumor cells as they are shown to express MHCI. Although there are barriers yet to overcome, the initial data suggest the feasibility of TIL therapy for PDAC.
P3 Synthetic biology approaches to enhance adoptive cell therapy safety and precision
Scott M Coyle1, Kole T Roybel1, Levi J Rupp1, Stephen P Santoro1, Stephanie Secrest1, Michael Spelman1, Hanson Ho1, Tina Gomes1, Tiffany Tse1, Chia Yung-Wu2, Jack Taunton3, Wendell Lim3, Peter Emtage1
1Cell Design Labs, San Francisco, CA, USA; 2Amgen, San Francisco, CA, USA; 3University of California San Francisco, San Francisco, CA, USA
Correspondence: Stephen P Santoro (firstname.lastname@example.org)
Chimeric antigen receptor T cells (CAR-T) have shown impressive efficacy against numerous hematological malignancies, yet a high percentage of individuals receiving these therapies experience toxicity in the form of cytokine release syndrome (CRS) and/or normal tissue destruction. Furthermore, solid tumors represent a substantive challenge for CAR therapy due to a lack of tumor- specific antigens and general inability of T cells to overcome immunosuppressive tumor microenvironments. We have sought to circumvent these obstacles by utilizing synthetic biology approaches to augment CAR-T function and specificity.
We developed two platform technologies that aim to mitigate toxicity associated with CAR-T therapy and endow T cells with environmental sensing capabilities that enhance tumor discrimination from normal tissue and/or confer the ability to generate customizable response outputs. Firstly, we engineered an “ON-switch” CAR that consists of two protein modules that undergo heterodimerization and become competent for signaling only in the presence of a small-molecule dimerizing agent . In addition, we created a “synthetic Notch” (synNotch) receptor, which we previously described in the context of combinatorial antigen sensing , that is capable of driving expression of any number of downstream polypeptides in response to antigen engagement.
Here we describe advances in our ON-switch CAR design that allow for dose-dependent antigen-specific T cell activation in the presence of an FDA-approved non-immunosuppressive small molecule dimerizer. Furthermore, we demonstrate that our synNotch T cells are able to deliver therapeutic payloads capable of, but not limited to, modulating the tumor microenvironment and changing the cell-intrinsic transcriptional properties of the synNotch T cells.
We have successfully identified a heterodimerizing switch receptor that specifically activates T cells in the presence of an FDA-approved non-immunosuppressive small molecule. The ability to control the potency of the CAR-mediated immune response in this way may reduce the toxicity associated with CAR-T therapy. Furthermore, we have demonstrated that synNotch T cells are able to sculpt the anti-tumor immune response in both a T cell intrinsic (transcriptional programing) and T cell extrinsic (therapeutic payload) manner, providing a customizable platform for altering T cell function and the tumor microenvironment.
1. Wu C-Y, Roybal KT, Puchner EM, Onuffer J, Lim, WA: Remote control of therapeutic T cells through a small molecule-gated chimeric receptor. Science 2015 350: aab4077.
2. Roybal KT, Rupp LJ, Morsut L, Walker WJ, McNally KA, Park JS, Lim W: Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits. Cell 164: 770–779.
Biomarkers and Immune Monitoring
P4 Evaluation of anticancer immunity in patients with thyroid cancer with a focus towards developing effective combination immunotherapy
Tarsem Moudgil1, Carmen Ballesteros-Merino1, Traci Hilton2, Christopher Paustian2, Rom Leidner3, David Page4, Walter Urba4, Bernard Fox1, Bryan Bell3, Ashish Patel1
1Providence Portland Medical Center, Portland, OR, USA; 2UbiVac, Portland, OR, USA; 3Earle A. Chiles Research Institute, Robert W. Franz Cancer Center, Providence Portland Medical Center, Portland, OR, Portland, OR, USA; 4Earle A. Chiles Research Institute, Providence Cancer Center, Portland, OR, USA
Correspondence: Bernard Fox (email@example.com)
Thyroid cancer is the most common endocrine-related cancer with 64,330 diagnoses expected this year. While the majority of these cancers are curable, almost 2% of these cancers are anaplastic thyroid cancers, which are highly aggressive and almost uniformly lethal. At the same time, the thyroid is known for being inherently immunogenic. For these reasons and due to an active surgical practice providing regular resections of thyroid cancers, we undertook a study of thyroid cancer with the idea of developing an immunotherapy for this disease.
We have developed a thyroid cancer tumor bank to complement our Oral, Head and Neck Cancer Program. This tumor bank cryopreserves enzymatically isolated viable cells from resected tumors (n = 16).We are also attempting to develop primary cell lines and are isolating and assessing autologous tumor-specific functions of tumor-infiltrating lymphocytes (TIL) (n = 7).
To date we have established 3 tumor cell lines from thyroid cancer specimens and identified PD-L1 expression on 2 of 2 tested. While numbers are small, preliminary analyses suggest that TIL cultures can be generated from 85% of thyroid cancer specimens and that autologous tumor-reactive TIL can be detected in 43% (n = 7) of thyroid cancers. Since not every tumor appears to contain TIL capable of recognizing autologous tumor, strategies to prime tumor-specific T cells represents an area of interest. DPV-003 is a microvesicle vaccine, DRibble, that contains more than 80 proteins that are overexpressed by thyroid cancer (TCGA provisional RNASeq n = 509 pts). The vaccine also contains a number of DAMPs and agonist activity for multiple TLRs packed into stable double membrane microvesicles that are targeted to CLEC9A+ antigen presenting cells. We are also developing a second thyroid-specific DRibble vaccine from a cell line derived from an anaplastic thyroid cancer.
Almost half of thyroid cancers evaluated, including one anaplastic thyroid cancer, contain T cells capable of recognizing autologous cancer cells and secreting IFN-g. However, the other 50% of thyroid cancers appear to lack tumor-reactive T cells and may benefit from combination immunotherapy strategies that include a vaccine.
Support: Steve and Cindy Harder, Robert W. and Elsie Franz, Wes and Nancy Lematta, Lynn and Jack Loacker, and The Chiles foundation (BAF).
P5 Development and clinical translation of 89Zr-Df-IAB22M2C for detecting CD8+ T Cells for immunotherapy applications
Tove Olafsen1, Daulet Satpayev2, Michael Torgov1, Filippo Marchioni1, Jason Romero1, Ziyue Karen Jiang1, Charles Zamilpa1, Jennifer S Keppler1, Alessandro Mascioni1, Fang Jia1, Chen-Yu Lee1, Jean Gudas1
1ImaginAb Inc., Inglewood, CA, USA; 2AdicetBio, Inc., Menlo Park, CA, USA
Correspondence: Jean Gudas (firstname.lastname@example.org)
Immunotherapies are changing the landscape for cancer treatment; however, the field is hampered by the lack of biomarkers that can be used for patient selection and for monitoring treatment responses rapidly and non-invasively. To address this need, ImaginAb is developing 89Zr-Df-IAB22M2C, an ~80 kDa minibody (Mb) with high affinity to the CD8 glycoprotein (binding EC50 = 0.4 nM) conjugated with desferrioxamine (Df) and radiolabeled with the positron emitting radionuclide Zirconium-89 (89Zr; T1/2 78.4 hours) for imaging CD8+ T cells in humans.
A comprehensive preclinical program that included evaluation of the in vitro and in vivo pharmacodynamics of IAB22M2C (unconjugated Mb), Df-IAB22M2C (conjugated Mb intermediate), Zr-Df-IAB22M2C (Zr chelated, conjugated non-radiolabeled form of final drug) and 89Zr-Df-IAB22M2C (radioactive final drug product) was conducted to demonstrate the safety and potential efficacy of the probe.
In vitro studies using human PBMCs from 10 individual human donors showed no measurable or reproducible impact on proliferation, activation or depletion of CD8+ T cells and no consistent release of cytokines when donor CD8+ T cells were exposed to soluble or immobilized Mb protein. Studies that evaluated the effect of saturating concentrations of 89Zr-Df-IAB22M2C on proliferation and viability of CD8+ T cells in vitro, also showed no impact on these parameters. Preclinical imaging and biodistribution studies demonstrated favorable pharmacokinetics and the ability of 89Zr-Df-IAB22M2C to detect infiltrating CD8+ T cells in a mouse hu-PBMC NSG™ GvHD model and in MatrigelTM plugs implanted with different numbers of human CD8+ T cells. Radiation dosimetry studies conducted in hu-CD34 NSGTM mice and the results GLP dosimetry analysis showed that on average, the organs receiving the largest dose equivalent were the kidneys at 8.0 rem/mCi (2.2 mSv/MBq) followed by the liver at 7.9 rem/mCi (2.1 mSv/MBq) and LLI wall at 6.5 rem/mCi (1.8 mSv/MBq). A GLP toxicology study was conducted in cynomolgus monkeys that included multiple dose cohorts of Zr-Df-IAB22M2C and a vehicle control. The results showed that doses up to 25 mg/kg of Zr-Df-IAB22M2C administered weekly to cynomolgus monkeys did not result in any treatment-related findings in survival, clinical signs, body weights, food consumption, ophthalmic examinations, electro-cardiology, blood pressure, heart rate, clinical and anatomic pathology, peripheral blood lymphocyte population, and cytokine levels.
89Zr-Df-IAB22M2C has the desired sensitivity and safety profile for imaging CD8+ T cells and the first-in-human studies will commence in the Q4 2016.
P6 High dose interleukin- 2 (HD IL-2) select trial in melanoma: a tissue and blood collection protocol to identify predictive biomarkers of benefit to HD IL-2 in patients with advanced melanoma
Ryan J Sullivan1, Yujin Hoshida2, Theodore Logan3, Nikhil Khushalani4, Anita Giobbie-Hurder5, Kim Margolin6, Joanna Roder7, Rupal Bhatt8, Henry Koon9, Thomas Olencki10, Thomas Hutson11, Brendan Curti12, Shauna Blackmon13, James W Mier8, Igor Puzanov14, Heinrich Roder7, John Stewart15, Asim Amin16, Marc S Ernstoff14, Joseph I Clark17, Michael B Atkins18, Howard L Kaufman19, Jeffrey Sosman20, Sabina Signoretti8, David F McDermott8
1Medical Oncology Department, Massachusetts General Hospital, Boston, MA, USA; 2Hess Center for Science and Medicine; Tisch Cancer Institute, New York, NY, USA; 3Simon Cancer Center, Indiana University, Indianapolis, IN, USA; 4H. Lee Moffitt Cancer Center, Tampa, FL, USA; 5Department of Biostatistics & Computational Biology, Boston, MA, USA; 6Department of Medical Oncology, City Of Hope, Duarte, CA, USA 7Biodesix, Inc., Boulder, CO, USA; 8Beth Israel Deaconess Medical Center, Boston, MA, USA 9Case Western Reserve University, Cleveland, OH, USA; 10The Ohio State University, Columbus, OH, USA; 11Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX, USA; 12Earle A. Chiles Research Institute, Providence Cancer Center, Portland, OR, USA; 13Massachusetts General Hospital Cancer Center, Boston, MA, USA; 14Roswell Park Cancer Institute, Buffalo, NY, USA; 15Wake Forest Baptist Medical Center, Winston Salem, NC, USA; 16Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC, USA; 17Loyola University Medical Center, Maywood, IL, USA; 18Georgetown-Lombardi Comprehensive Cancer Center, Washington , DC, USA; 19Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA; 20Robert Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA
Correspondence: Ryan J Sullivan (email@example.com)
HD IL-2 provides objective responses in 15-20% and durable complete remission in 5-8% of patients with metastatic melanoma (MM). We previously identified a gene expression-based tumor subclass characterized by immune related genes (Class 2; C2) associated with durable response to HD IL-2 compared to the remaining tumors that overexpressed lineage-associated genes (Class 1; C1). The primary objective of the HD IL-2 select trial in melanoma was to prospectively validate the favorable gene expression signature (C2). Secondary objectives were to seek serum and tissue biomarkers of durable response.
170 patients with MM were enrolled at 15 Cytokine Working Group sites from 2010 to 2014. All patients had formalin-fixed paraffin-embedded (FFPE) tumor tissues identified and blood drawn prior to HD IL-2. Tumor assessments used WHO criteria and investigator-assessed outcomes. RNA extracted from FFPE tumor tissues was used for whole transcriptome profiling by RNA sequencing (114 samples yielded sufficient RNA, 101 passed default Quality Control (QC)). Pretreatment serum from 114 patients served as the test set and was analyzed using matrix-assisted laser desorption/ionization (MALDI) and machine-based learning algorithms to identify a predictive protein expression signature.
Thirty-one of 170 pts (18.2%) responded, and median overall survival was 21.3 months, with a 40 month median follow-up. Analysis of RNAseq from 101 patients whose specimens passed QC showed that a C2 signature was associated with response to HD IL-2 (normalized enrichment score 1.70, false discovery rate 0.004). Using MALDI, a protein expression signature enriched for acute phase proteins (including CRP, IL-6, and SAA) was defined in the pre-treatment serum and used to classify 39 patients into group A (non-acute phase protein expression) and 75 patients in group B (acute phase protein expression). Complete response rate in group A was 21% and zero in group B (p = 0.0001). Two-year PFS rate was 29% in group A compared to 4% in group B (p = 0.0005).
In this prospective biomarker validation study, HD IL-2 produced durable remissions and prolonged survival in patients with MM. A tumor-derived gene expression signature enriched for immune-related genes was associated with response. Additionally, preliminary data with a serum protein signature appears to identify patients most likely to have a complete response.
ClinicalTrials.gov identifier NCT01288963.
P7 Pharmacodynamic gene expression changes from talimogene laherparepvec (T-VEC) plus ipilimumab in a phase Ib study for metastatic melanoma
Abraham A Anderson1*, Igor Puzanov2, Mohammed M Milhem3, Robert HI Andtbacka4, David Minor5, Kevin S Gorski1, Daniel M Baker1, Omid Hamid6, Howard L Kaufman7
1Amgen Inc., Thousand Oaks, CA, USA; 2Roswell Park Cancer Institute, Buffalo, NY, USA; 3University of Iowa Hospitals and Clinics, Iowa City, IA, USA; 4University of Utah, Huntsman Cancer Institute, Salt Lake City, UT, USA; 5California Pacific Melanoma Center, San Francisco, CA, USA; 6The Angeles Clinic & Research Institute, Los Angeles, CA, USA; 7Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA
Correspondence: Abraham A Anderson (firstname.lastname@example.org)
T-VEC is a herpes simplex virus type-1 based oncolytic immunotherapy designed to selectively replicate in tumors, produce GM-CSF, and stimulate antitumor immune responses. Ipilimumab is a checkpoint inhibitor that promotes T cell activation by blocking negative signaling through CTLA-4. Both agents have demonstrated activity as monotherapy in advanced melanoma. Based on the potential complementary MOA of the agents, tumor cell lysis and antigen presentation (T-VEC) in combination with T cell checkpoint inhibition, we hypothesized that improved efficacy was possible when the agents are used in combination. Because the safety profiles are non-overlapping, the combination was not anticipated to have significant increased toxicity. To address these hypotheses, a phase Ib/II study evaluating the safety and efficacy of T-VEC plus ipilimumab for Stage III-IV metastatic melanoma was initiated. The phase Ib study was completed (N = 19) with no DLTs (primary endpoint) or new safety signals with combination treatment, and an ORR of 50% . Phase Ib also included biomarker analyses investigating potential pharmacodynamic markers for T-VEC monotherapy and in combination with ipilimumab.
Nineteen patients received T-VEC at 106 PFU/mL at week 1, then 108 PFU/mL Q2W from week 4. Ipilimumab was given at 3 mg/kg Q3W starting at week 6 for 4 infusions. Peripheral blood was obtained (Paxgene RNA) at baseline and at weeks 4, 6, 9, and 15. Gene expression (Agilent Microarray) was analyzed for changes in expression level with treatment. Pharmacodynamic markers were identified with a linear mixed effects model. False discovery was controlled with permutation testing.
Gene expression was measured in 16 patients in phase Ib. Most treatment effects on expression were seen after ipilimumab treatment, but there were a few effects in the initial T-VEC phase that passed false discovery controls. These T-VEC effects included SELV, SYNPO, ZBTB32, IQCF2, CDC27, KLK1, PRR20B, CHST6, and IGH. ZBTB32 has been reported to control the proliferative burst of virus-specific natural killer cells responding to infection. The combination effects were enriched for genes involved in lymphoid tissue structure and development and immune cell trafficking. 185 of these genes had signs of a T-VEC effect in the monotherapy phase. These included increases in GZMM, PDCD1, CD8B, CD8A, and CTLA4 and decreases in IL18, IRAK3, and TXNRD1.
This hypothesis-generating microarray analysis identified genes upregulated in circulating peripheral blood cells after T-VEC monotherapy and combination treatment. We plan to further evaluate these genes and other potential pharmacodynamic markers in phase II.
ClinicalTrials.gov identifier NCT01740297.
1. Puzanov I, Milhem MM, Minor D, Hamid O, Li A, Chen L, et al: Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma. J Clin Oncol 2016, 34:2619–2626.
Clinical Trials in Progress
P8 Phase I study of alpha-tocopherlyoxyacetic acid in patients with advanced cancer: immune response and pharmacokinetics results
Emmanuel Akporiaye1, Brendan Curti2, Yoshinobu Koguchi2, Rom Leidner3, Kim Sutcliffe3, Kristie Conder3, Walter Urba2
1Veana Therapeutics Inc, Portland, OR, USA; 2Earle A. Chiles Research Institute, Providence Cancer Center, Portland, OR, USA; 3Earle A. Chiles Research Institute, Robert W. Franz Cancer Center, Providence Portland Medical Center, Portland, OR, USA
Correspondence: Emmanuel Akporiaye (email@example.com)
Alpha-tocopheryloxyacetic acid (α-TEA) targets tumor cell mitochondria to release reactive oxygen species (ROS) that induce immunogenic cell death (ICD), antigen release, and enhanced antigen cross-presentation in pre-clinical models. α-TEA is being evaluated for safety and tolerability in a first-in-human phase I trial in patients with advanced cancers (NCT02192346). Tumor types in the ongoing trial include renal cancer, esophageal adenocarcinoma, thyroid cancer, duodenal cancer, and squamous cell carcinoma of the head and neck.
α-TEA lysine salt is administered orally to patients and given daily in escalating doses for 28 days. Immune monitoring of peripheral whole blood was conducted for all 12 patients at baseline, and at 1 week and 4 weeks post-treatment. Plasma levels of α-TEA have been determined so far in patients receiving 2.4 mg/kg and 4.8 mg/kg α-TEA at 1, 4, 8, and 24 hours after the first dose. Additional samples were evaluated on days 8, 15, 22, and 29 before the planned α-TEA dose on those days.
Twelve patients have been treated so far at 2.4 mg/kg and 4.8 mg/kg dose levels. Eight patients have stable disease, lasting from 1 to 22+ months. One patient showed more than a 2-fold increase in the number of activated (CD38+ HLA-DR+) effector CD8+ T cells 1 week post-treatment. A second patient showed more than a 2-fold increase in the number of activated effector memory CD8+ T cells 4 weeks post-treatment. Both patients experienced stable disease over 5 and 22 months, respectively. Evaluation of α-TEA levels at the 2.4 mg/kg and 4.8 mg/kg doses revealed a proportional increase in α-TEA plasma levels over a 28-day interval without any indication that steady state plasma levels were reached. Of the 12 patients, 6 developed atrial fibrillation (AF) after starting α-TEA. The earliest event occurred 7 days post-treatment, but AF was more common 29-56 days post-treatment. Four of the 6 patients had a medical history of AF. These were grade 2 events by CTCAE 4.0 criteria and managed with appropriate medication without further sequelae.
α-TEA treatment resulted in stable disease in 80% of patients lasting between 1 and 22+ months. AF was observed commonly in patients with a medical history of AF, and was managed with appropriate medication. No clinically meaningful grade 3 or 4 toxicities were observed. Plasma α-TEA levels increased proportionally without any indication that steady state levels were achieved. α-TEA may function through enhancing pre-existing CD8+ T cell-mediated anti-tumor activity.
P9 Phase I, first-in-human, open label, dose escalation study of MGD009, a humanized B7-H3 x CD3 dual-affinity re-targeting (DART®) protein in patients with B7-H3-expressing neoplasms or B7-H3 expressing tumor vasculature
Anthony W Tolcher1, Evan W Alley2, Gurunadh Chichili3, Jan E Baughman4, Paul Moore3, Ezio Bonvini3, Syd Johnson3, Sadhna Shankar3, James Vasselli3, Jon Wigginton3, John Powderly5
1START - South Texas Accelerated Research Therapeutics, LLC, San Antonio, TX, USA; 2Penn Presbyterian Medical Center, University of Pennsylvania, Philadelphia, PA, USA; 3MacroGenics, Inc., Rockville, MD, USA; 4MacroGenics, Inc., South San Francisco, CA, USA; 5Carolina BioOncology Institute, PLLC, Huntersville, NC, USA
Correspondence: Jan E Baughman (firstname.lastname@example.org)
MGD009 is a B7-H3 x CD3 dual affinity re-targeting (DART) protein. DART proteins are bispecific, antibody-based molecules that can bind two distinct antigens simultaneously. MGD009 is designed to redirect T cells to eliminate B7-H3-expressing target cells through co-engagement of B7-H3 on the target cell and CD3 on the T cell, each in a monovalent binding manner. MGD009 contains a mutated human IgG1 Fc domain to reduce/eliminate binding to Fc gamma receptors (FcγRs) and complement, but retains binding to the neonatal Fc receptor (FcRn) enabling use of the IgG salvage pathway to prolong its circulating half-life. B7-H3 protein expression is limited in normal human tissues, but is overexpressed in a broad range of tumor types, including melanoma, non-small cell lung cancer (NSCLC), squamous cell carcinoma of the head and neck (SCCHN), mesothelioma, and urothelial cancer. By binding to B7-H3 on tumor cells and CD3 on T lymphocytes, MGD009 can recruit cytotoxic T cells, irrespective of their ability to recognize cancer cells, and trigger T cell activation, expansion, and T cell-mediated killing of B7-H3-expressing tumors. The limited expression of B7-H3 on normal cells should restrict the potential for cytolytic activity directed at normal tissues, and unintended toxicity in patients treated with MGD009.
This multi-center, open-label trial is a phase I dose escalation/cohort expansion study. All patients must have advanced B7-H3-positive tumors. Prior checkpoint inhibitor therapy will be allowed. Dose escalation uses a 3+3+3 design, with patients treated every 2 weeks with escalating doses of IV MGD009 (starting dose 0.3 ug/kg). The dose escalation phase enrolls patients with mesothelioma, bladder cancer, melanoma, SCCHN, NSCLC, clear cell renal cell carcinoma, ovarian cancer, thyroid cancer, triple-negative breast cancer, pancreatic cancer, colon cancer, soft tissue sarcoma, or prostate cancer. Cohort expansions (n=16/cohort) treated at the maximum tolerated dose will include patients with melanoma, SCCHN, mesothelioma, urothelial cancer, and NSCLC. Pre- and on-study biopsies are required for melanoma patients in the cohort expansion phase. Primary and secondary study objectives include characterization of the safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of MGD009. All tumor evaluations will be carried out by both Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and immune-related RECIST.
ClinicalTrials.gov identifier NCT02628535.
P10 Intratumoral Flt3L and poly-ICLC combined with low dose radiotherapy: a novel in situ vaccine for incurable indolent lymphomas
Thomas Marron1, Nina Bhardwaj1, Linda Hammerich1, Fiby George1, Seunghee Kim-Schulze1, Tibor Keler2, Tom Davis2, Elizabeth Crowley2, Andres Salazar3, Joshua Brody4
1Icahn School of Medicine at Mount Sinai, New York, NY, USA; 2Celldex Therapeutics, Hampton, NJ, USA 3Oncovir, Inc., Washington, DC, USA; 4Mount Sinai School of Medicine, New York, NY, USA
Correspondence: Thomas Marron (email@example.com)
Lymphomas are the 5th most common cancer in the United States, and unlike more aggressive lymphomas, indolent non-Hodgkin lymphoma (iNHL) and is incurable with standard therapy. A previous trial of in situ vaccination in iNHL combined intratumoral injection of a TLR9 ligand with radiation to induce a systemic immune response against tumor. This approach induced tumor-specific CD8+ T cell responses and durable clinical remissions of patients’ untreated sites of disease were seen in a minority of patients. One limitation in this previous trial may have been the scarcity of intratumoral dendritic cells (DCs); DCs are uniquely able to endocytose dying tumor cells for cross-presentation to tumor antigen-specific CD8+ T cells. In our novel iteration of in situ vaccine, intratumoral FMS-like tyrosine kinase 3 ligand (Flt3L) is introduced as a priming step to increase the presence of intratumoral DCs. Flt3L induced tumor leukocyte infiltration and regression in lymphoma tumors in pre-clinical trials, and CDX-301- a formulation of Flt3L - was previously shown to mobilize BDCA-1 and BDCA-3 myeloid DC subsets in an early phase clinical trials. These DC subsets respond to several TLR agonists and cross-present antigens more effectively than plasmacytoid DCs (pDCs). While pDCs are high expressers of TLR9, responsive to CpG, myeloid dendritic cells express a wider array of TLRs, including high levels of TLR3.
This phase I/II trial tests the hypothesis that this novel in situ vaccination will induce clinical remissions at distant (untreated) tumor sites in two cohorts of patients with either previously untreated or relapsed/refractory iNHL (n = 15 per group). Intratumoral CDX-301 25ug/kg is injected into a palpable lymph node for 9 days, followed by 2Gy local radiotherapy on day 9 and 10 to the target lymph node. To activate local DCs, poly-ICLC 2 mg is injected on day 10, 14, 17, and weekly thereafter for a total of 8 treatments.
Exploratory endpoints include measuring induction of systemic tumor-specific immune response in pre- and post-vaccine blood and tissue samples. Using flow cytometry and CyTOF, we have confirmed that CD1c + (BDCA1+) and CD141+ (BDCA3+) DCs home to treated tumors following treatment with Flt3L and T cells attain a mature effector phenotype. Tissue from initial bx is being sequenced, and candidate neoantigens being determined in silico; these neoantigens are then being synthesized and tested for potential to activate patient pre- and post-vaccination T cells.
This trial is in process.
ClinicalTrials.gov identifier NCT01976585.
P11 Preliminary safety and efficacy data for radiotherapy and PD-L1 checkpoint blockade in metastatic non-small cell lung cancer: is timing everything?
Arta Monjazeb1, Megan E Daly2, Jonathan Riess2, Tianhong Li2, William J Murphy1, Karen Kelly2
1University of California, Davis, Sacramento, CA, USA; 2University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA
Correspondence: Arta Monjazeb (firstname.lastname@example.org)
Inhibition of the PD-1/PD-L1 checkpoint pathway can induce rapid and durable responses in patients with non-small cell lung cancer (NSCLC). Unfortunately the majority of patients fail to respond and there is interest in exploring combinatorial strategies to improve response rates. One such strategy is combining checkpoint inhibition with radiotherapy (RT). We report here our pre-clinical data for combining radiotherapy with PD-L1 checkpoint blockade. These data demonstrate a clear influence of the sequencing of combinatorial therapy on its efficacy. Based on these data, we have initiated a clinical trial testing sequencing strategies of radiotherapy with PD-L1 inhibition in patients with metastatic NSCLC.
Using syngeneic mouse tumor models, we tested the synergy of combining RT with PD-L1 inhibition and the influence of the sequencing of these therapies on efficacy. Based on this preclinical work, we have initiated a phase II clinical trial testing this combinatorial strategy with three cohorts. The three cohorts are concurrent therapy, radiotherapy followed by PD-L1 checkpoint blockade, and PD-L1 blockade followed by radiotherapy. We report here the preliminary safety, efficacy, and correlative science data from interim analysis of the safety run-in for this trial.
In studies using syngeneic mouse tumor models, we find that PD-L1 inhibition provides no added benefit to radiotherapy alone when administered after radiotherapy. Conversely, priming of the immune system with anti-PD-L1 prior to RT provides significant synergy of the combinatorial therapy. Our clinical trial has completed enrollment to the safety-run in of 6 patients. In total, 2 patients experienced grade 3 dose limiting toxicities meeting the criteria for completion of the safety-run in without the need for dose de-escalation. One patient experienced asymptomatic grade 3 lymphopenia and one patient experienced both grade 3 lymphopenia and grade 3 failure to thrive. At twelve weeks post-treatment initiation, 83% of patients experienced response or disease stability. Three patients (50%) had abscopal responses by RECIST criteria, two patients (33%) had stable disease, and one patient (17%) had progressive disease.
Pre-clinical data suggests that sequencing may be key to the success of combinatorial strategies of PD-L1 blockade and RT. The safety run-in for combining PD-L1 checkpoint inhibition with RT suggests that the combination is safe and tolerable in metastatic NSCLC. The trial will continue to accrual to evaluate different sequencing strategies for combining RT and PD-L1 checkpoint blockade. Further study is needed to evaluate the efficacy and optimal sequencing of RT + PD-L1 checkpoint blockade.
P12 Tissue factor is a novel oncotarget in triple negative breast cancer and BRAF- mutated melanoma for immunotherapy using a second generation ICON (L-ICON) in monotherapy and combination therapy
Zhiwei Hu1, Rulong Shen2, Amanda Campbell2, Elizabeth McMichael2, Lianbo Yu2, Bhuvaneswari Ramaswam2, Cheryl A London2, Tian Xu3, William Carson2
1The Ohio State University Wexner Medical Center and The OSU James Comprehensive Cancer Center, Columbus, OH, USA; 2The Ohio State University, Columbus, OH, USA; 3Yale University, New Haven, CT, USA
Correspondence: Zhiwei Hu (email@example.com)
The objective of this study is to identify tissue factor (TF) as a novel oncotarget for triple negative breast cancer (TNBC) and BRAF mutated melanoma, both of which are very difficult to treat in clinic, and to develop a novel TF-targeting agent for immunotherapy. To achieve this goal, Hu developed a second generation TF-targeting ICON, named L-ICON, which consists of only the light chain (1-152 aa) of FVII fused to an IgG1Fc. The effects of L-ICON were evaluated as monotherapy or combination therapy with interleukin 15 (IL-15) for the malignancies.
TF expression was determined by immunohistochemistry or by flow cytometry. L-ICON protein (GenBank accession no. KY760097) and replication-deficient adenoviral vectors have been developed. Binding activity of L-ICON was determined. Its ADCC effect was evaluated by an ADCC effector assay and coagulation activity by FVII chromogenic activity assay. L-ICON efficacy in monotherapy and combination therapy with IL-15 was tested in mouse models of murine and human breast cancer (4 T1 and TNBC MDA-MB-231) and melanoma (B16F10 and BRAF mutated SK-Mel-28).
TF is over-expressed on TNBC cells and the tumor neovasculature in over 85% of TNBC patients (n = 14) when using standard paraffin-embedded tumor tissues or in nearly 60% of TNBC patients (n = 157) when employing tissue microarray slides. Importantly, TF expression is not detected in normal breast tissues. L-ICON has several important improvements over its first generation ICON, including (i) more than 50% reduction in molecular mass, (ii) complete elimination of coagulation activity, (iii) stronger binding activity to TNBC and (iv) more effective as monotherapy in vivo in orthotopic and subcutaneous mouse models of human TNBC (MDA-MB-231) and murine cancer 4 T1 (an animal stage IV human breast cancer) and B16F10. L-ICON monotherapy and combination with IL-15 were effective for the treatment of SK-Mel-28 in SCID mouse models.
TF is a novel biomarker and oncotarget in TNBC and BRAF- mutated melanoma. L-ICON, a novel TF-targeting ICON, was effective in monotherapy and combination therapy with IL-15 for the treatment of murine and human TNBC and melanoma in vitro and in vivo in preclinical mouse models.
This work was partly supported by a startup fund from OSUMC, a Seed Award from the OSUCCC TT Program, a Phase 1 L-Pilot Award from OSU CCTS via NCATS Award Number UL1TR001070 and the Dr. Ralph and Marian Falk Medical Research Trust. IL-15 was obtained from the NCI Preclinical Repository. Z.H. is the inventor of L-ICON and its uses (US Patent Application # 62/082,891).
P13 Beta-adrenergic blockade improves the immunotherapeutic response to melanoma
Kathleen M Kokolus1, Elizabeth A Repasky2, Todd D Schell1, Joseph D Drabick1
1The Pennsylvania State University College of Medicine, Hershey, PA, USA; 2Roswell Park Cancer Institute, Buffalo, NY, USA
Correspondence: Kathleen M Kokolus (firstname.lastname@example.org)
Recent developments in immunotherapy have made enormous strides towards expanding the scope of cancer treatment by targeting a patient’s own immune cells. Despite these advances, malignant melanoma remains a significant clinical issue with a high proportion of patients remaining unresponsive to therapy and improved, but still low, complete response rates. The body’s response to stress is closely integrated with the immune response, yet few cancer treatment strategies account for the relationship between these biological systems. When the stress response is activated, neurotransmitters, including norepinephrine, which bind β-adrenergic receptors (βARs) located on the surface of immune cells, are released, leading to regulation of various immune cell functions. βAR signaling can be prevented pharmaceutically with βAR antagonists (β-blockers) and considerable literature suggests that these drugs, which are commonly prescribed for other indications including hypertension, are associated with positive outcomes in cancer patients. We examined the effects of βAR blockade on the efficacy of two immunotherapies approved to treat metastatic melanoma: IL-2, which promotes T cell proliferation and αPD-1, which impacts T cell activation.
C57BL/6 J mice with established B16.F10 melanomas were treated with β-blockers and immunotherapy (αPD-1, IL-2 or αPD-1/IL-2) and tumor growth was monitored throughout each treatment regimen. The accumulation of immune cells within the tumors and lymphoid tissues were evaluated by flow cytometry at multiple time points following treatment.
Blockade of βAR signaling beginning after tumors were established had no significant impact on tumor growth. In contrast, attenuation of tumor growth by each immune-based therapy was improved in the presence of β-blockers. We observed significantly extended survival in mice treated with αPD-1 or αPD-1/IL-2 combined with β-blockers compared to immunotherapy only mice. Most importantly, the combination of β-blockers, αPD-1 and IL-2 produced a highly significant delay in tumor growth and prolonged survival compared to αPD-1/IL-2 without β-blockers.
Blocking βAR signaling improved the efficacy of at least two types of immunotherapy, but was most effective when administered with dual-immunotherapy. We suggest that each therapeutic component may improve a unique aspect of the immune response to maximally delay melanoma progression. Due to the availability of all three components for use in humans, this therapeutic regimen can potentially be clinically translated to expand the population of metastatic melanoma patients who experience long term benefits from immune-based therapies.
This work was supported by CURE Grant SAP #4100072562 (Pennsylvania Department of Health) and NIH/NCI 5 T32 CA060395 (KMK). IL-2 was generously provided by Prometheus Laboratories Inc.
P14 Sequentially targeting upregulated TIM-3 and CTLA-4 does not rescue the attenuated therapeutic efficacy of combination immunotherapy with OX40 costimulation and PD-1 blockade
David J Messenheimer1, Shawn Jensen2, Bernard Fox2
1Earle A. Chiles Research Institute, Portland, OR, USA; 2Providence Cancer Center, Portland, OR, USA
Correspondence: David J Messenheimer (email@example.com)
Combination immunotherapy targeting checkpoint molecules has shown substantial results against solid tumors. However as novel therapies targeting costimulatory molecules are introduced into the clinic, successful combination with checkpoint blockade remains uncertain. Some strongly immunogenic preclinical models have shown benefit when combining anti-OX40 and anti-PD-1 treatment. In contrast, using a PD-1 refractory mammary tumor model we have demonstrated that a significant anti-tumor effect generated with OX40 costimulation is significantly attenuated with the addition of PD-1 blockade. We noted high levels of inflammatory cytokines in the serum of combination treated mice, and also saw a significant increase in inhibitory receptors TIM-3, LAG-3, and CTLA-4 on CD4+ and CD8+ T cells in the periphery of treated mice. We hypothesized that the upregulation of these other inhibitory receptors were limiting the efficacy of anti-OX40 plus anti-PD-1 combination treatment, and tested whether sequentially blocking these receptors could augment therapeutic efficacy.
Established orthotopically transplanted MMTV-PyMT mammary tumors in FVB/NJ mice were treated with three doses of anti-OX40 and anti-PD-1 every other day. Serum was taken at time points and tested for cytokine concentration and spleens were taken two days after treatment to measure surface expression of inhibitory and costimulatory receptors. Combination treated mice were then followed by three doses of anti-TIM-3 with or without anti-CTLA-4.
The addition of anti-TIM-3 and CTLA-4 provided no additional impact to tumor growth compared to that provided by anti-OX40 and anti-PD-1 (n = 7/group, two independent experiments).
P15 Novel IL-2/mAb complexes mediate potent anti-tumor immunity which is augmented with anti-PD-1 mAb therapy
Mark Rubinstein1, Kristina Andrijauskaite1, Marzena Swiderska-syn1, Kristin Lind2, Agnes Choppin2, Marina K Roell2
1Medical University of South Carolina, Charleston, SC, USA; 2XOMA Corporation, Berkeley, CA, USA
Correspondence: Mark Rubinstein (firstname.lastname@example.org)
Recent success and FDA approval of immune checkpoint inhibitors (CI) in a growing number of cancers are transforming cancer treatment and revitalizing interest in immunotherapies. However, while efficacy is observed in patients with advanced metastatic diseases treated with CI, not all patients respond and most responses are incomplete. Preclinical studies suggest that combinations of additional modalities will provide opportunities to improve patient responses. As both IL-2 and CI therapy can independently augment anti-tumor immunity in patients, likely in mechanistically distinct ways, we hypothesized we could improve anti-tumor immunity by combining IL-2 and anti-PD-1 mAb therapy.
To improve IL-2 efficacy and therapeutic index, we generated novel anti-IL-2 mAbs which, when complexed with IL-2 (IL-2/mAb) offer advantages over standard IL-2 therapy [1-3]. First, binding to an anti-IL-2 mAb increases IL-2 half-life and biological activity. Second, depending on the epitope at which the mAb binds to IL-2, antibody binding can modulate which IL-2 receptor subunits (alpha, beta, or gamma) are engaged. Antibodies that interfere with binding of IL-2Rα can reduce activation of high- IL-2Rα-expressing cell types, such as suppressive Tregs, and steer activity toward cell types expressing only IL-2Rβ and γ. In this way, these complexes may have more effective anti-tumor activity [1-3]. We screened antibody phage libraries to identify antibodies that shift IL-2 receptor binding and activity differentially on different cell types in vitro and in vivo. Complexes of these antibodies were tested in vivo for their effects on T cell frequency and activation, and in a subcutaneous Lewis lung carcinoma model for their ability to mediate anti-tumor immunity, both alone and in combination with anti-PD-1 mAb.
In normal mice, IL-2/mAb complexes potently expanded CD8+ T cells and NK cells with minimal expansion of Tregs. As single agent therapy, IL-2/mAb complexes or anti-PD-1 mAb reduced tumor growth, although most mice succumb to tumor growth eventually. Combination of IL-2/mAb complexes with anti-PD-1 mAb therapy resulted in durable, complete responses in nearly half of the mice.
While immune based therapies such as anti-PD-1 mAb can be highly effective in select patients, even in those patients that obtain clinical benefit, disease may recur. Our results suggest that the addition of IL-2/mAb complexes to therapy with anti-PD-1 mAb could broadly increase the percentage of patients deriving benefit from immune-based therapy.
1. Sato, et al: Biotherapy 1993, 6(3):225–231.
2. Boyman, et al: Science 2006, 311:1924–1927.
3. Létourneau, et al: PNAS 2010, 107:2171–2176.
P16 The combination of an IL-15/IL-15Ralpha complex (ALT-803) and anti-PD-1 mAb leads to superior anti-tumor immunity in a murine lung tumor model
John Wrangle1, Kristina Andrijauskaite1, Marzena Swiderska-syn1, Peter Rhode2, Hing Wong2, Mark Rubinstein1
1Medical University of South Carolina, Charleston, SC, USA; 2Altor BioScience Corporation, Miramar, FL, USA
Correspondence: Mark Rubinstein (email@example.com)
Administration of antibodies that block the PD-1/PD-L1 pathway has demonstrated unprecedented success in mediating clinical responses in patients with advanced cancer. These antibodies are thought to act by blocking the ability of PD-L1 to mediate an inhibitory signal to PD-1 expressing T cells during antigen-recognition. These antibodies are now FDA-approved for multiple cancers including non-small cell lung cancer (NSCLC) in patients with disease that has progressed during or after platinum-based chemotherapy. In these patients, one in five patients can attain a clinical response while on checkpoint inhibitor therapy. While promising, this therapy fails to induce a durable clinical response in most patients. To overcome this limitation, we hypothesized that combinatorial therapy with anti-PD-1 mAb and a lymphocyte growth factor would more effectively augment the expansion of tumor-reactive lymphocytes. This would also provide a means to not only remove inhibitory pathways but directly augment the function of tumor-reactive lymphocytes. We chose to use an IL-15/IL-15Ra complex (ALT-803) composed of an IL-15 mutant (N72D) that was pre-associated with the soluble IL-15Ra/Fc fusion protein. This superagonist complex has been shown to potently expand and activate CD8+ T cells and NK cells in various animal models.
To assess the efficacy of combination therapy, we injected C57BL/6 mice subcutaneously with Lewis lung carcinoma. Mice with established tumors were treated with anti-PD-1 mAb and/or IL-15/IL-15Ra complex, and we monitored tumor progression and changes in immune cell populations in the periphery and tumor.
The combination of anti-PD-1 mAb and the IL-15/IL-15Ra complex was substantially more effective at inducing complete responses compared with administration of either agent alone. Effective therapy was associated with the expansion of CD8+ T cells and NK cells, and the acquisition of the ability of CD8+ T cells to produce IFNγ after activation. Interestingly, in vitro, IFNγ led to upregulation of both MHC and PD-L1 on tumor cells, suggesting a mechanistic basis for the improved efficacy of the combination therapy.
Our results suggest that the efficacy of anti-PD-1 mAb therapy may be improved by co-administration of the IL-15/IL-15Ra complex. Our results also suggest a mechanistic basis for why the combination may be superior to single agent therapy. To determine if this combination would be of value in human patients, we have initiated a phase Ib/II clinical trial (NCT02523469) to assess the combination of anti-PD-1 mAb (nivoluamb) in combination with ALT-803 in patients with refractory advanced NSCLC.
P17 Functional dichotomy of PI3K isoforms in CD4 T cells provides a strategy for selectively targeting regulatory T cells to enhance anti-tumor immunotherapy
Shamim Ahmad1, Mason Webb1, Rasha Abu-Eid1, Rajeev Shrimali1, Vivek Verma1, Atbin Doroodchi1, Zuzana Berrong1, David Yashar1, Raed Samara2, Mikayel Mkrtichyan1, Samir Khleif1
1Georgia Cancer Center, Augusta, GA, USA; 2Qiagen, Frederick, MD, USA
Correspondence: Samir Khleif (firstname.lastname@example.org)
The PI3K-Akt signaling pathway modulates diverse biological responses including signaling, proliferation and survival of T cells. The identification of a signaling pathway, which differentially regulates regulatory T cells (Tregs) and conventional T cells (Tconvs), is crucial for selectively modulating these two subsets. The differential role of class IA PI3K isoform in regulating the survival and apoptosis of Tregs and Tconvs has not been elucidated yet.
For in vitro experiments sorted Tregs and Tconvs were labeled with CellTrace TM Violet Cell Proliferation stain (VCT) according to the manufacturer’s protocol (Life Technologies, NY). Cells were stimulated with and without inhibitors. For in vivo experiments C57BL/6 Mice were injected subcutaneously (s.c.) with TC-1 tumor cells and monitored for development of tumors. Vaccine was given weekly s.c. For therapeutic experiments vaccine was given weekly throughout the experiment. CAL-101 treatment was provided on the day when tumor size reached 3-4 mm 5-6 day before vaccination.
Here, we report that PI3Kd isoform is sufficient for TCR downstream signaling, proliferation, and survival for either Tconvs or Tregs. In Tregs, however, PI3Kd is a dominant isoform, where Tregs are fully dependent on PI3Kd to regulate these properties as PI3Kα and PI3Kb do not play any role in these biologic processes. On the other hand, in Tconvs, the two other isoforms, PI3Kα and PI3Kb combined, provide redundant pathway to PI3Kd in the regulation of TCR signaling, proliferation and survival. This redundant role provided by PI3Kα and PI3Kβ isoforms to PI3Kd in Tconvs offers a selective therapeutic approach to inhibit Tregs, where by inhibiting PI3Kd, signaling, proliferation, and survival are inhibited in Tregs, while PI3Kα and PI3Kβ, will provide a path for Tconvs to proliferate and function.
Importantly, we demonstrate that our findings translate to therapeutic efficacy in vivo, where the inhibition of PI3Kδ, enhanced anti-tumor efficacy of antigen-specific vaccine by decreasing the suppressive Tregs and increasing the number of vaccine-induced CD8 T cells, thus showing synergistic therapeutic effect against tumors. Our findings provide a strategy for the selective targeting of Tregs in the frame of cancer combination immunotherapy.
These findings provide a new insight into CD4 T cell biology and offer a new strategy for selective targeting of Tregs in the frame of development of anti-cancer immunotherapies.
Combinations: Immunotherapy/Standard of Care
P18 Pembrolizumab in combination with chemoradiotherapy (CRT) for locally-advanced squamous cell carcinoma of the head and neck (SCCHN): Interim safety analysis (ISA)
Steven Powell1, Mark Gitau2, Christopher Sumey1, Andrew Terrell2, Michele Lohr1, Ryan K Nowak1, Steven McGraw3, Ash Jensen2, Miran Blanchard2, Kathryn A Gold4, Ezra EW Cohen4, Christie Ellison1, Lora Black1, John Lee5, William Chad Spanos1
1Sanford Cancer Center, Sioux Falls, SD, USA; 2Sanford Roger Maris Cancer Center, Fargo, ND, USA 3Sanford Health, Sioux Falls, SD, USA; 4Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA; 5NantKwest, Inc., Culver City, CA, USA
Correspondence: Steven Powell (email@example.com)
Blockade of the programmed death receptor 1 (PD-1) interaction with its ligands (PD-L1, PD-L2) represents an active therapeutic approach in recurrent and metastatic SCCHN . This immune checkpoint may allow immune escape during standard treatment, including CRT . Standard CRT in SCCHN has substantial toxicity and the safety of adding PD-1 inhibition is unknown. We report the first ISA of weekly cisplatin-based CRT in combination with pembrolizumab, a humanized IgG4 monoclonal antibody inhibitor of the PD-1:PD-L1/2 interaction.
This is an open-label phase IB trial of pembrolizumab used in combination with cisplatin-based, definitive CRT in patents with stage III-IVB SCCHN. The treatment schema is outlined in Fig. 5. Key inclusion and exclusion criteria are in Fig. 6. The primary endpoint of safety is assessed by dose-limiting grade ≥3 adverse events (AEs) and immune-related AEs (irAEs) per NCI-CTCAE v4.0 criteria. Efficacy is measured by RECIST v1.1 complete response (CR) rate on 100-day post-CRT imaging and/or pathologic CR for those who undergo salvage surgery. Planned enrollment is 39 patients based on a hypothesized CR rate of >60% and a two-stage Simon minimax design (type I error rate of 0.05 and power of 0.80). Secondary endpoints will include overall response, survival, and quality-of-life assessments.
At the time of ISA, 27 patients have been enrolled. Patient and disease characteristics are in Fig. 7. At data cut-off on 9/14/2016, 22 patients have completed CRT. Of those patients, 3 required cisplatin dose reductions and 6 required a dose discontinuation. Acute grade (G) ≥ 3 AEs for those completing CRT are in Fig. 8. Median cumulative cisplatin dose is 225 mg/m2. There were no radiation dose-limiting toxicities. Two patients (9%) discontinued pembrolizumab due to irAEs (G2 peripheral motor neuropathy and G3 transaminase elevation). No deaths have occurred.
This represents one of the first studies to evaluate the safety of concurrent CRT and PD-1 inhibition in SCCHN. Acute CRT-related toxicities are comparable to other SCCHN CRT studies. No new immunologic safety signals were seen. Further investigation of this approach is warranted.
Funding supported by the Merck Investigator Studies Program.
ClinicalTrials.gov identifier: NCT02586207
1. Seiwert TY, et al: Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol 2016, 17(7):956–965.
Diet, Exercise and/or Stress and Impact on the Immune System
P19 Exercise training reduces splenic accumulation of MDSCs and delays tumor progression in a therapeutic breast cancer model
Erik Wennerberg1, Emily Schwitzer2, Claire Lhuillier1, Graeme Koelwyn3, Rebecca Hiner2, Lee Jones2, Sandra Demaria4
1Weill Cornell Medicine, New York, NY, USA; 2Memorial Sloan Kettering Cancer Center, New York, NY, USA; 3New York University School of Medicine, New York, NY, USA; 4Department of Radiation Oncology, Weill Cornell Medicine, New York, NY, USA
Correspondence: Erik Wennerberg (firstname.lastname@example.org)
Epidemiological studies show a correlation between physical activity and cancer-related mortality . However, the contribution of immune mediated anti-tumor immunity to the beneficial effects of exercise has yet to be defined . We sought to investigate if forced running would have a therapeutic benefit in mice bearing a poorly immunogenic breast cancer and investigate the immunological changes occurring in response to exercise.
On day 0 Balb/c mice were inoculated with 4 T1 breast cancer cells subcutaneously in the right flank (n = 6/group). Starting on day 7, once tumors were palpable, mice were subjected to 30 minutes of forced treadmill running (18 cm/sec) five days per week. Control mice remained sedentary throughout the study. Analysis of immune cells in spleen and tumor was performed at day 17 and 32 and spontaneous lung metastases were evaluated at day 32.
We observed a significantly delayed primary tumor growth (tumor volume on day 31: 1167 ± 174 mm3 in sedentary versus 847 ± 124 mm3 in exercised mice, p < 0.01) and a tendency for reduced metastatic burden in the lungs of exercised compared to sedentary mice. The progressive marked increase in myeloid-derived suppressor cells (MDSCs) and splenomegaly seen in sedentary 4 T1 tumor-bearing mice was less pronounced in exercised mice. This difference was significant on day 17; with spleen weight (520 ± 110 mg in sedentary versus 330 ± 30 mg in exercised mice, p < 0.01) and MDSC frequency in spleen leukocytes (22.7 ± 2.6% in sedentary versus 14.3 ± 2.7% in exercised mice, p < 0.001) were significantly lower in exercised mice compared to sedentary mice. Furthermore, on day 32, the CD8+ T cell/Treg and CD8+ T cell/MDSC ratio showed a tendency to increase in tumors from exercised mice.
Our data demonstrate that exercise can slow tumor progression in a therapeutic setting. While the mechanisms of this effect require further investigation, the observed decrease in the proportion of immunosuppressive immune cells in spleen and tumor of exercised mice is likely to play a role. Importantly, the ability of exercise to reduce immunosuppression locally and systemically supports testing exercise in combination with immunotherapy as a therapeutic modality that can increase responses without increasing toxicity.
1. Ballard-Barbash R, Friedenreich CM, Courneya KS, Siddiqi SM, McTiernan A, Alfano CM: Physical activity, biomarkers, and disease outcomes in cancer survivors: a systematic review. Natl Cancer Inst 2012, 104:815–840.
2. Koelwyn GJ, Wennerberg E, Demaria S, Jones LW: Exercise in Regulation of Inflammation-Immune Axis Function in Cancer Initiation and Progression. Oncology 2015, 29(12).
Not Listed – Other
P20 Systemic immunotherapeutic efficacy of an immunocytokine, NHS-muIL12, in a superficial murine orthotopic bladder cancer model
Vandeveer Amanda, John W Greiner, Jeffrey Schlom
Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
Correspondence: Vandeveer Amanda (email@example.com)
Interleukin-12 is one of the most powerful proinflammatory cytokines capable of supporting T and NK cell function, inducing IFNγ while driving a TH1 adaptive immune response. Its success as an antitumor agent in preclinical models has yet to be realized in a clinical setting due to systemic toxicity. An IL-12 delivery system has been developed to maximize deposition of the cytokine directly in the tumor microenvironment (TME), while mitigating the dose-limiting systemic effects.
NHS-IL12 is a novel immunocytokine, consisting of two molecules of human or murine IL-12 fused to a tumor necrosis-targeting human IgG1 (NHS76). NHS76 recognizes exposed chromatin-DNA found in necrotic human/murine tumors. Previous studies have shown selective tumor uptake of NHS-IL12 in necrotic subcutaneous murine tumors. Urothelial bladder cancer is known to respond favorably to immunotherapeutic agents due to many somatic mutations and TILs, and response to Bacillus Calmette-Guerin (BCG).
We evaluated the use of NHS-muIL12 in a murine orthotopic bladder cancer model. MB49Luc cells, instilled into the bladder form superficial, multifocal tumors which can be monitored with a luciferase-based intravital imaging system. NHS-muIL12 is a very potent anti-tumor agent in both MB49 tumor models, reducing tumor volume in a dose-dependent manner. In the intravesical bladder model, antitumor effects were seen at 2.5 mg/kg administrated as three separate systemic injections. Mice were cured of tumor when treated at 20 mg/kgx3 NHS-muIL12 with durable tumor-free long-term survival. Immune analyses revealed TAA-specific CTLs and IFN-γ responses, indicating the development of a specific anti-tumor immune response. An immune memory response protected mice following re-challenge with MB49 tumor cells. Anti-tumor efficacy required CD4+ or CD8+ T cells as depletion of either abrogated the anti-tumor effects. Evaluation of TILs by FACS, revealed that NHS-muIL12 significantly reduced the number of immune suppressive cells such as MDSCs, 24 hours post-treatment, which continued to the end of the study. Immunofluorescence showed correlative treatment-related modulation of CD4+ and CD8+ T cells as well as MDSCs and Tregs within the TME. Gene expression of RNA from bladder tumors, identified various immune components with immunosuppressive or immune potentiating roles, modulated by NHS-muIL12 treatment.
These data support the possibility that NHS-muIL12 abrogates an immune-suppressive response within the TME, which might permit T cells to execute their antitumor effects. NHS-huIL12 (MSB0010360N; M9241), is currently being evaluated against solid tumors in a phase I clinical trial (NCT01417546).
We acknowledge the kind contribution of NHS-muIL12 from EMD Serono, Billerica, MA.
Therapeutic Cancer Vaccines
P21 Intracellular trafficking of self-assembled immune signals
Michelle Bookstaver, Christopher M Jewell
Fischell Department of Bioengineering, University of Maryland - College Park, College Park, MD, USA
Correspondence: Michelle Bookstaver (firstname.lastname@example.org)
We recently exploited electrostatic interaction to design self-assembling nanostructures comprised entirely from peptide antigens and toll-like receptor (TLR) agonists as adjuvants. These materials simplify vaccine composition and exhibit unique properties such as direct control over the absolute and relative concentrations of each component and co-delivery of the signals to antigen presenting cells. In pre-clinical models of melanoma, this approach leads to significantly enhanced anti-tumor immunity. Here, we study how the physicochemical features (e.g., peptide charge) and relative concentration of each component impact the internalization, trafficking, and processing of the immune signals in antigen presenting cells.
FITC-labeled SIINFEKL peptide was modified with three or nine arginines, for use as a cationic anchor to support self-assembly with a polyanionic nucleic acid-based TLR3 agonist, polyIC. Hollow capsules built from these signals were synthesized by coating a sacrificial CaCO3 core with alternating layers of modified SIINFEKL and PolyIC. After deposition, the core was removed using EDTA and capsules were washed with buffer, resulting in stable capsules formed from immune signals. Capsule size was determined by image analysis and component loading levels were determined by fluorimetry using FITC-labeled peptide and Cy5-labeled TLRa. Stability studies were carried out by incubating capsules in media as a function of different pH and ionic strengths. For uptake and trafficking studies, murine splenocytes were isolated and treated with different concentrations of capsules. Cells were analyzed by flow cytometry and imaging in the presence or absence of inhibitors of endocytic processes and during staining with markers for surface proteins and intracellular organelles.
Capsules loaded with FITC-SIINFEKL-R9 and PolyIC were 1-2 μm in diameter and exhibited similar size and shape for 2 weeks when in buffer. These materials exhibited tunable loading with a composition of 15.5% peptide and 84.5% TLRa used for trafficking studies. FITC-SIINFEKL-R9 and PolyIC capsules were efficiently internalized through energy dependent processes (i.e., endocytosis) when incubated with primary dendritic cells within 1 hour of treatment. These effects were also found to be dose-dependent and did not impact viability of treated cells.
Initial studies reveal capsules comprised of FITC-SIIN-R9 and PolyIC are uptaken by primary immune cells quickly and effectively. Ongoing studies will assess the uptake of capsules by endocytosis in the presence of inhibitors to decipher the endocytic pathway and trafficking of capsules through lysosomes and endosomes.
This work was supported in part by NSF CAREER # 1351688 and Alliance for Cancer Gene Therapy # 15051543.
P22 Analysis of B and T cell responses in non-small cell lung cancer (NSCLC) patients enrolled in a phase II trial of cyclophosphamide with allogenic DRibble vaccine (DPV-001)
Christopher Paustian1, Andrew Gunderson1, Brian Boulmay2, Rui Li3, Bradley Spieler4, Kyle Happel4, Tarsem Moudgil5, Zipei Feng6, Carmen Ballesteros-Merino3, Christopher Dubay6, Brenda Fisher7, Yoshinobu Koguchi8, Sandra Aung1, Eileen Mederos4, Carlo B. Bifulco3, Michael McNamara9, Keith Bahjat9, William Redmond9, Augusto Ochoa4, Hong-Ming Hu10, Adi Mehta11, Fridtjof Lund-Johansen11, Bernard Fox6, Walter Urba8, Rachel E. Sanborn8, Traci Hilton1
1UbiVac, Portland, OR, USA; 2Section of Hematology/Oncology, Louisiana State University, New Orleans, LA, USA; 3Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Cancer Center, Portland, OR, USA; 4Louisiana State University Stanley S. Scott Cancer Center, New Orleans, LA, USA; 5PPMC, Portland, OR, USA; 6Providence Cancer Center, Portland, OR, USA; 7Providence Medical Center, Portland, OR, USA; 8Earle A. Chiles Research Institute, Providence Cancer Center, Portland, OR, USA; 9Providence Medical Center, Portland, OR, USA; 10UbiVac, Providence Medical Center, Portland, OR, USA; 11Oslo University Hospital, Oslo, Norway
Correspondence: Christopher Paustian (email@example.com)
DRibble vaccines are microvesicles derived from proteasome-blocked autophagosomes. The DPV-001 DRibble vaccine is derived from an adenocarcinoma and a mixed histology cancer cell line. By mass spectroscopy they contain more than 130 potential NSCLC antigens, many as prospective altered-peptide ligands, which could intensify their immunogenicity. In preclinical models, DRibble immunotherapy provided significant cross-protection against 8 of 9 tumors tested. Additionally, Dribble vaccines are effective in treating established tumors in preclinical combination immunotherapy models. We hypothesize that the efficacy of DRibbles’ vaccination can be attributed to their capacity to present tumor-derived short-lived proteins (SLiPs) and defective ribosomal products (DRiPs) that are typically not processed and presented by professional antigen presenting cells. These SLiPs and DRiPs embody a prospective pool of tumor antigens against which the host may be less tolerant.
Thirteen definitively-treated stage III NSCLC patients were vaccinated at 3-week intervals. Patients were randomized such that some patients’ intradermal vaccines were combined with administration of imiquimod or GM-CSF as an adjuvant. PBMCs and serum were collected at baseline and at each vaccination. For one patient, PBMCs from the baseline visit and week 12 were tested against that patient’s autologous tumor cell line to measure increased tumor specific T cell activation. Studies are currently underway to evaluate changes in TCR repertoires. CD4+ and CD8+ T cells from multiple time points were sorted and TCR sequencing is being performed to look at alterations in the T cell repertoire. The primary outcome measure of this clinical trial was to discover if vaccine alone, vaccine plus imiquimod, or vaccine plus GM-CSF generated the greatest number of strong antibody response.
Serum from the baseline visit and week 12 was analyzed for increased antibody response to >9000 human proteins using ProtoArrays and Microsphere Affinity Proteomics. Where sufficient tumor was available, whole exome sequencing was done to evaluate whether antibody and T cell responses were directed to mutations, altered peptide ligands or overexpressed normal proteins.
Compared to vaccination alone or vaccination with GM-CSF, vaccination with DPV-001 plus imiquimod significantly (p < 0.05) increased the number of antibody responses that were four-fold higher at week twelve. In the one patient where autologous tumor was available, vaccination increased the tumor-specific release of TNF-alpha by peripheral blood CD4 T cells.
Based on these studies, future trials will combine the adjuvant imiquimod with DRibble vaccine. Trial Registration
ClinicalTrials.gov identifier: NCT01909752
P23 An open-label phase I/IIa escalating dose study to evaluate safety and T cell immunogenicity of PDS0101 in subjects with cervical intraepithelial neoplasia (CIN) and high-risk HPV infection
Frank Bedu-Addo1, Greg Conn1, Michael King1, Panna Dutta1, Robert Shepard2, Mark Einstein3
1PDS Biotech, New Brunswick, NJ, USA; 2PDS Biotech, Miami Beach, FL, USA; 3Rutgers, NJ Medical School, Newark, NJ, USA
Correspondence: Robert Shepard (RShepard@Post.Harvard.edu)
Current HPV vaccines are effective at preventing infection. However, there are no therapeutic vaccines to treat the infection or commonly associated diseases e.g. CIN, cervical, anal and oral cancers. A therapy that is simple, effective and safe enough to be administered to CIN and early-stage cancer patients could be important in achieving the goal of effective cancer prevention and treatment of pre-metastatic cancer. We assessed whether PDS0101, a combination of modified multi-epitope HPV16 peptides (HPVmix) and escalating doses of the synthetic Versamune® T cell activating platform could facilitate antigen cross-presentation and safe immune activation leading to strong HPV-specific CD8+ T cell induction in CIN.
Safety and immunogenicity were assessed in an open label dose escalation study. Groups of 3-6 subjects received either low dose (1 mg), medium dose (3 mg) or high dose (10 mg) of Versamune® cationic lipid with 2.4 mg of HPVmix. Each subject received one SC dose every 3 weeks for a total of 3 doses. T cell response was evaluated by IFN-γ and granzyme-b ELISpot using blood drawn from the subjects pre-vaccination, 2 weeks after each vaccination and 90 days after vaccination 3. The trial is registered at ClinicalTrials.gov (number NCT02065973).
No serious adverse events were reported. No IND safety reports were submitted. No subjects withdrew. Strong HPV-specific T cell responses occurred at all 3 doses, even in those subjects with low pre-vaccination T cell responses. PDS0101 vaccination led to strong T cell responses evaluated by both IFN-γ and granzyme-b ELISpot. Conclusions: PDS0101 is safe and effectively performs antigen cross-presentation as demonstrated by HPV-specific T cell responses, including inducing active cytolytic T cells. Clinical benefit in CIN2/3 and cancer will be evaluated in larger phase II trials.
PDS0101 is safe and effectively performs antigen cross-presentation as demonstrated by HPV-specific T cell responses, including inducing active cytolytic T cells. Clinical benefit in CIN2/3 and cancer will be evaluated in larger phase II trials.
ClinicalTrials.gov identifier: NCT02065973
P24 Effects of TLR7 agonist imiquimod combined with local radiotherapy on the tumor microenvironment in women with metastatic breast cancer in a prospective trial
Sylvia Adams1, Ena Wang2, Ping Jin3, Yelena Novik1, Debra Morrison1, Ruth Oratz1, Franco M Marincola2, David Stroncek4, Judith Goldberg1, Sandra Demaria5, Silvia C Formenti5
1Perlmutter Cancer Center, New York University School of Medicine, NYC, NY, USA; 2Sidra Medical and Research Center, Doha, Qatar; 3National Institutes of Health Clinical Center Department of Transfusion Medicine, Bethesda, MD, USA; 4National Institutes of Health Clinical Center, Bethesda, MD, USA; 5Weill Cornell Medicine, Department of Radiation Oncology, New York, NY, USA
Correspondence: Sylvia Adams (firstname.lastname@example.org)
Application of TLR7 activator imiquimod (IMQ) onto BCC of the skin leads to an early tumoral transcriptional profile of immunological rejection (ICR) preceding complete remission as shown in a randomized trial . Here we employed the same methodology evaluating serial FNA tumor biopsies from breast cancer patients treated on a clinical trial of the combination of IMQ and radiotherapy (RT), to delineate dynamic changes associated with ICR in breast cancer and to understand the contribution of each treatment modality to antitumor immunity in vivo. We previously demonstrated synergy of IMQ/RT in the poorly immunogenic TSA model with enhanced T cell-mediated inhibition of treated and untreated tumors .
Clinical trial (NCT01421017): for patients with metastatic breast cancer to the skin. Treatment: topical IMQ to one metastasis, IMQ and RT to another metastasis. IMQ self-applied 5xX/per week x 8 weeks, RT started with first IMQ (6Gyx5 over 10 days). Cyclophosphamide (200 mg/m2 IV) was administered a week before in a subset of patients. An untreated, measurable lesion (skin or distant metastases) outside the IMQ and radiation fields was observed as systemic response read-out per RECIST1.1. Local response defined as PR or CR in treated lesions. FNA of IMQ and IMQ/RT treated metastases: at baseline, 2 and 3 weeks, RNA isolation/amplification performed per SOPs. Gene expression: Affymetrix Human GeneArray 1.0 ST/Partek Genomics suite software with special emphasis on expected immune signature.
Serial FNA samples are available from 18 patients. Gene expression profiles of baseline biopsy treated with IMQ/RT identified 2309 differentially expressed genes (p < 0.005) between CR and PR. Among them, ICR genes such as GZMB, GZMH, PRF1, GNLY, CD8A and TBX21 are over expressed in CR. Significant altered gene expression was observed in progressing lesions (week 3 vs baseline, 1854 genes) in contrast to responding metastases (PR: 53 genes, CR: 23 genes) post IMQ/RT suggesting active wound healing and tumor progression signature. For the IMQ alone treated metastases, differential gene expression was observed at baseline distinguishing subsequent PR and PD (n = 189, p < 0.005). Systemic response was observed as a marked baseline gene expression difference (n = 1177, p < 0.005) predicting abscopal phenomena (CR, PR, SD and PD).
The ICR signature in tumors before IMQ-RT treatment is positively correlated with complete local response, which validates the ICR hypothesis in metastatic breast cancer. Systemic response consistent with induction and/or boosting of adaptive immunity is predicted by significant enrichment of immune signature.
ClinicalTrials.gov identifier: NCT01421017
1. Panelli: Genome Biol 2008.
2. Dewan: CCR 2012.
P25 Immunoscore as a prognostic marker in stage I-III colon cancer: results of a SITC-led global validation study
Jérôme Galon1, Bernhard Mlecnik1, Florence Marliot1, Fang-Shu Ou2, Carlo B Bifulco3, Alessandro Lugli4, Inti Zlobec4, Tilman T Rau4, Iris D Nagtegaal5, Elisa Vink-Borger5, Arndt Hartmann6, Carol Geppert6, Michael H. Roehrl7, Prashant Bavi7, Pamela S Ohashi7, Julia Y Wang7, Linh T Nguyen7, SeongJun Han7, Heather L MacGregor7, Sara Hafezi-Bakhtiari7, Bradley G Wouters7, Yutaka Kawakami8, Boryana Papivanova8, Mingli Xu8, Tomonobu Fujita8, Shoichi Hazama9, Nobuaki Suzuki9, Hiroaki Nagano9, Kiyotaka Okuno10, Kyogo Itoh11, Eva Zavadova12, Michal Vocka12, Jan Spacek12, Lubos Petruzelka12, Bohuslav Konopasek12, Pavel Dundr12, Helena Skalova12, Toshihiko Torigoe13, Noriyuki Sato13, Tomohisa Furuhata13, Ichiro Takemasa13, Marc Van den Eynde14, Anne Jouret-Mourin14, Jean-Pascal Machiels14, Tessa Fredriksen1, Lucie Lafontaine1, Bénédicte Buttard1, Sarah Church1, Pauline Maby1, Helen Angell1, Mihaela Angelova1, Angela Vasaturo1, Gabriela Bindea1, Anne Berger1, Christine Lagorce1, Prabhu S Patel15, Hemangini H Vora15, Birva Shah15, Jayendrakumar B Patel15, Kruti N Rajvik15, Shashank J Pandya15, Shilin N Shukla15, Yili Wang16, Guanjun Zhang16, Giuseppe V Masucci17, Emilia K Andersson17, Fabio Grizzi18, Luigi Laghi18 Gerardo Botti19, Fabiana Tatangelo19, Paolo Delrio19, Gennaro Cilberto19, Paolo A Ascierto19, Franco Marincola20, Daniel J Sargent2, Bernard A Fox3, Franck Pages1
1INSERM, Université Pierre et Marie Curie, Université Paris Descartes, Paris, France; 2Mayo Clinic, Rochester, MN, USA; 3Earle A. Chiles Research Institute, Providence Cancer Center, Portland, Oregon, USA; 4Institute of Pathology, University of Bern, Bern, Switzerland; 5Radboud University Nijmegen Medical Center, Nijmegen, Netherlands; 6University Erlangen-Nürnberg, Erlangen, Germany; 7Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada; 8Division of Cellular Signaling, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan; 9Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University Graduate School of Medicine, Ube, Japan; 10Department of Surgery, Kinki University Faculty of Medicine, Osaka-Sayama, Japan; 11Division of Clinical Research, Research Center for Innovative Cancer Therapy, Kurume University School of Medicine, Kurume, Japan; 12First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic; 13Sapporo Medical University, Sapporo, Japan; 14Institut Roi Albert II, Cliniques universitaires St-Luc, Université Catholique de Louvain, Brussels, Belgium; 15The Gujarat Cancer & Research Institute, Ahmedabad, India; 16Institute for Cancer Research, Xi’an Jiaotong University, Xi’an, China; 17Karolinska Institutet, Karolinska University, Stockholm, Sweden; 18Humanitas Clinical and Research Center, Rozzano, Italy; 19Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy; 20Sidra Medical and Research Center, Doha, Qatar
Correspondence: Bernard A Fox (email@example.com)
Increasing evidence has illustrated that enhanced lymphocytic infiltration is a powerful prognostic marker in colon cancer (CC). The Immunoscore (IM) methodology was developed as a standardized assay to quantify the in situ immune cell infiltrate.
The Society for Immunotherapy of Cancer (SITC) led an international consortium, initiated with 23 expert centers from 17 countries, to evaluate the Immunoscore in routine clinical settings. CC patients (pts) stages I/II/III with no prior neo-adjuvant treatment were included in this study. Overall, 3855 pts split into a training set (TS), internal validation set (IVS), and external validation set (EVS) were quantified for IM using immunohistochemistry with CD3/CD8 antibodies and digital pathology quantification of whole slide sections. All statistical analyses were pre-defined and performed by external statisticians. The primary endpoint was time-to-recurrence (TTR); multivariate analyses were performed using Cox models adjusted for IM, age, gender, T-stage, N-stage, and stratified by participating center.
Across centers, the median recurrent follow-up was 126.6 months. Pt characteristics: 51.5% male, median age 69 years, and 17%/54%/29% stage I/II/III, respectively. Among pts with stages I-III CC in the TS, TTR was shorter among 152 pts (22%) with Low-IM CC vs. 548 pts with High-IM CC (HR [95% CI], 0.41 [0.28-0.61]; P < 0.0001). In the IVS, TTR was also shorter among 155 pts with Low-IM CC vs. 481 pts with High-IM CC (0.41 [0.27-0.65]; P < 0.0001). In the EVS, TTR was also shorter among 225 pts with Low-IM CC vs. 744 pts with High-IM CC (0.51 [0.38-0.68]; P < 0.0001). These results were independent of age, sex, tumor stage, and sidedness. Among secondary objectives, Immunoscore groups (High, Int, Low) predicted time to recurrence in the TS (0.19 [0.10-0.37]; P < 0.0001), IVS (0.27 [0.14-0.53]; P < 0.0001), and EVS (0.33 [0.22-0.49]; P < 0.0001). In stage II CC pts (1433), the difference in TTR was significant between the Low and High-Immunoscore groups (0.36 [0.23-0.56]; P < 0.0001). In multivariate models, Immunoscore grouping (2, 3, or 5) was significant (C-index : 0.73 [0.66-0.80], all P < 0.0001). Multivariate models including MSI and sidedness were performed and will also be presented. Reproducibility of the IM assay was validated across centers.
The primary and secondary endpoints of the global Immunoscore study were reached. Overall, TTR was significantly longer in pts with stages I-III CC defined as High-IM. Moreover, a subgroup of patients with high-risk stage II CC was also identified by Low-IM.
This initiative was supported by a variety of sources, including funding from Definiens, Prometheus, and a grant from the Czech Ministry of Health, 15-28188A and League against cancer.
P26 Defining critical features of the immune microenvironment in melanoma
Robyn Gartrell1, Douglas Marks1, Edward Stack2, Yan Lu1, Daisuke Izaki3, Kristen Beck4, Dan Tong Jia4, Paul Armenta4, Ashley White-Stern4, Yichun Fu4, Zoe Blake1, Howard L Kaufman5, Bret Taback1, Basil Horst1, Yvonne M Saenger6
1Columbia University Medical Center, New York, NY, USA; 2Perkin Elmer, Hopkinton, MA, USA; 3Columbia University, New York, NY, USA; 4Columbia University College of Physicians and Surgeons, New York, NY, USA; 5Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA; 6New York Presbyterian/Columbia University Medical Center, New York, NY, USA
Correspondence: Robyn Gartrell (firstname.lastname@example.org)
Precise biomarkers are urgently needed to characterize the tumor immune micro-environment, both for prognostication and to predict the benefit of immuno-therapeutic intervention. HLA-DR on tumor cells and Ki67 on cytotoxic (CD8+) T cells have been proposed as biomarkers of anti-PD1 activity. Multiplex immunohistochemistry (mIHC) allows for automated quantitation of phenotypes and spatial distributions of immune cell populations within formalin fixed paraffin embedded (FFPE) tissues.
In order to test whether mIHC can better characterize the tumor immune microenvironment, we screened databases at the Herbert Irving Cancer Center (HICC) at Columbia University for early stage melanoma patients with available FFPE primary melanoma tissue and documented clinical follow up. We identified a preliminary population of 31 stage II-III melanoma patients diagnosed between 2000 and 2012, with characteristics shown in Fig. 9 for whom pathology from the primary biopsy was shown. Clinical follow up was available on 18 patients of whom 9 patients were alive with no evidence of recurrence, 1 had died of another malignancy, and 7 had died of melanoma. 15 patients had more than 24 months of survival information available but no detailed clinical information. 5 μm slides from either the primary biopsy or subsequent wide local excision procedure were stained using Opal multiplex IHC for DAPI, CD3 (LN10, Leica), CD8 (4B11, Leica), CD68 (KP1, Biogenex), SOX10 (BC34, Biocare), HLA-DR (LN-3, Abcam) and Ki67 (MIB1, Abcam). Cell phenotypes within representative fields pre-selected by a trained dermato-pathologist and were visualized using the Mantra quantitative pathology workstation (Perkin Elmer), and analysis of spatial distribution of CD3 + CD8+ cells analyzed as shown in Figs. 10 and 11 using inForm® image analysis software (Perkin Elmer), and Spotfire software (TIBCO).
CD3 + CD8+ cells are closer to both tumor (SOX10+) and CD68+ cells when they express HLA-DR (p < 0.001). Conversely, CD3 + CD8+ cells are significantly farther from Sox10+ cells when they express Ki-67. Among patients with clinical follow up, CD3 + CD8+ cells in non-recurrent patients were closer to SOX10+HLA-DR+ cells than they were in recurrent patients(p < 0.001).
P27 Immune profiling via multiplexed immunofluorescence shows that Imprime based anti-cancer efficacy involves profound changes in macrophage polarization, type 1 IFN signaling and the formation of immune cell clusters
Steven Leonardo, Keith Gorden, Ross B Fulton, Kathryn Fraser, Takashi O Kangas, Richard Walsh, Kathleen Ertelt, Jeremy Graff, Mark Uhlik
Biothera Pharmaceuticals Inc., Eagan, MN, USA
Correspondence: Steven Leonardo (email@example.com)
Imprime PGG (Imprime) is a soluble, intravenously (iv) administered yeast 1,3/1,6 β-glucan PAMP (pathogen-associated molecular pattern). As a PAMP, Imprime triggers innate immune function, including direct tumor killing, repolarization of the immunosuppressive tumor microenvironment (flipping immunosuppressive M2 macrophages to an anti-tumor M1 state), and T cell expansion and activation via dendritic cell maturation and antigen presentation. Clinically, Imprime has demonstrated promising efficacy in clinical trials when combined with tumor-targeting or anti-angiogenic antibodies. Phase II studies with pembrolizumab are starting in both metastatic triple negative breast cancer and metastatic melanoma. Herein, we have employed multiplexed immunofluorescence to profile the immune microenvironment in preclinical tumor tissues.
The B16F10 experimental metastasis model was used to interrogate Imprime’s anti-tumor activity in vivo. B16F10 melanoma cells were injected into the tail vein of syngeneic C57BL/6 mice, seeding the lungs with B16 foci. Outgrowth of these metastatic foci was assessed after treatment with the tumor-targeting anti-tryp1 antibody TA99, Imprime, or the combination. At various times post tumor injection, lungs were examined via multiplexed immunofluorescence (IFC) for markers of immune infiltration and activation. IFC was performed using 7-color staining (Opal technology, PerkinElmer) combined with in situ hybridization (RNAScope, ACD). Images were acquired with the Vectra3 multispectral imaging system and cells segmented using Inform (PerkinElmer). Imaging data were transformed into “.fcs” files and analyzed using Flowjo flow cytometry software (Treestar)). Relational parameters such as immune cell clustering and tumor infiltration were performed via custom algorithms in R.
TA99 alone suppressed the outgrowth of B16 lung metastases by 54% when compared to vehicle treatment. The combination of Imprime with TA99 reduced the number of metastases even more profoundly (96% vs vehicle). IFC analyses showed that Imprime specifically accumulates in the tumor stroma, binds to macrophages and elicits increased iNOS production, indicating the re-polarization of these macrophages to a more M1-like, inflammatory state. Imprime-treatment also triggered the formation of large immune cell clusters, possibly representing resolved tumor nests or the establishment of tertiary lymphoid tissues, both of which have been identified as predictors of successful anti-tumor immune responses. Finally, Imprime treatment and localization at the tumor site corresponds with substantial upregulation of the gene Mx1- a type 1 interferon-responsive gene.
Imprime is a potent immunomodulator that induces a coordinated immune attack in vivo demonstrated by immune cell binding, M1 re-polarization and a type-1 interferon signature that coincides with reduced outgrowth of established ling metastases.
P28 Local convection-enhanced delivery of PD-1 blockade antibody in de novo murine model of glioblastoma
Jennifer S Sims, Liang Lei, Takashi Tsujiuchi, Jeffrey N Bruce, Peter Canoll
Columbia University Medical Center, New York, NY, USA
Correspondence: Jennifer S Sims (firstname.lastname@example.org)
Systemic delivery of anti-PD1 antibody therapy has proven relatively safe in glioma patients, but therapeutic response remains unpredictable and persistently low. Checkpoint blockade antibodies face numerous potential confounders in these tumors, such as the blood-brain barrier, poor local or lymph node presentation of tumor antigens, and unknown dependency on PD-1/PD-L1 activity during tumor progression. Here, we conducted a pilot study using intracranial convection-enhanced delivery (CED) of anti-PD1 (mDX400) into a de novo murine glioma model to the dissect tumor and immune perturbations following local treatment, and to compare the efficacy of treating during early or late tumor progression.
Transgenic C57BL/6-PTEN(fl/fl) mice were injected with a retrovirus expressing PDGFb and cre recombinase, inducing tumorigenesis as previously described. In this model, with a median survival of 80 days post-tumor induction (D80), convergence to a stereotyped subset of genomic rearrangements occurs by approximately D35. Intracranial osmotic pumps filled with mDX400 or isotype control antibody solution were implanted at the tumor site for 14-day windows spanning (D28-D42) or following (D42-D56) this developmental transition, then removed. Tumor burden was monitored by bioluminescence (luciferase reporter), and mice were sacrificed upon presentation of tumor-related morbidity. Tissue was formalin-fixed for histopathology and cryopreserved for gene expression analysis.
During both treatment windows, tumor burden decreased differentially in mDX400-treated mice. While survival time between mDX400- and isotype-treated mice was nearly identical for D28-D42 (both median D70), for mice treated between D42-D56, median survival differed (D88 vs. D68), but without statistical significance between the groups (p = 0.25). Interestingly, the D42-D56 mDX400 group produced several “long-term survivors”, who lived up to 158 days with stable tumor burden. While substantial T cell infiltration was detected in the end-stage tumors of both mDX400- and isotype-treated mice by immunohistochemistry (CD3e), expression of immune signaling pathways (e.g., Fc receptor and Toll-like receptor families, phagosome/lysosome components), was significantly higher among three long-surviving mDX400-treated mice than in three isotype-treated mice.
Our pilot study of mDX400 administration by CED identified an impact on tumor burden during and following therapy, but a lack of survival benefit for D28-D42 treatment. While additional experiments are needed to statistically evaluate survival benefit for the later treatment window, differentially high intratumoral expression of genes reflecting immune activation among mDX400-treated, long-surviving mice demonstrates that molecular study in this model may elucidate intratumoral conditions associated with response to anti-PD1 blockade in glioma.
This pre-clinical study is supported by Merck & Co. Investigator-Initiated Sponsored Projects grant LKR146174.